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Chapter 1 Introduction 
1.1 Hyaluronic acid 
1.1.1 Structure and physicochemical properties 
Hyaluronic acid (HA), first isolated from the vitreous humour of bovine eyes by Karl 
Meyer in 1934,1 consists of repeating disaccharide units of [-> 4)-β-D-glucuronic 
acid(1-> 3)-β-D-N-acetylglucosamine(1-> ]n, where n can be up to 20000 and larger 
(Figure 1.1). 
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HOHO H
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Figure 1.1. Chemical structure of hyaluronic acid 
Hyaluronic acid (hyaluronan), along with chondroitin-, keratan- and dermatane sul-
fate, heparin and heparan sulfate, is a member of the family of glycosaminoglycanes 
which are mostly linear polymers of high molecular weight composed of aminosugars 
(N-acetylglucosamine or N-acetylgalactosamine) and uronic acids (glucuronic or idu-
ronic acid). In contrast to the other glycosaminoglycanes, HA is not subjected to any 
type of covalent modification, especially sulfation, during its synthesis.  
For decades, it was assumed that hyaluronan chains in solution were random coils. 
However, nuclear magnetic resonance studies of the shape of HA performed by J. E. 
Scott2 have shown that the HA chain may be stabilised in a helical conformation via 
internal hydrogen bonds. Each disaccharide unit is twisted by 180 degrees with re-
spect to both the preceding and the subsequent one. The total orientation of the 
hyaluronan chain is achieved by a second twist resulting in an overall two-fold helix. 
The striking feature of this helix is an extensive hydrophobic patch of about 8 CH-
groups of 3 carbohydrate units. In addition to the two-fold helix, based on X-ray fibre 
diffraction studies with stretched, semi-hydrated fibres and films of different salts of 
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hyaluronic acid, three-fold and four-fold single helices were detected.3 Molecular dy-
namics simulations of HA decasaccharide fragments revealed high flexibility and fast 
interconversion of hyaluronan conformations. In solution, high molecular weight so-
dium hyaluronate can be modelled as a highly extended structure with similar local 
conformations to those obtained from X-ray diffraction analysis and predicted by 
molecular dynamics.4 
These properties lead to very viscous solutions of high molecular weight HA, i.e. by 
binding water, the volume of HA increases by about 1000-fold compared to the non-
hydrated state.5 In the hydrated state, the diffusion of e.g. proteins and electrolytes is 
substantially facilitated. 
1.1.2 Occurrence and physiological importance 
As major constituent of the extracellular matrix, hyaluronan is present in the skin 
(about 50 % of the total HA in the body) but also in the vitreous humour of the eye 
(0.1-0.4 mg/g wet weight), in the synovial joint fluid (3-4 mg/ml), in the matrix pro-
duced by the cumulus cells around the oocyte prior to ovulation (~0.5 mg/ml), or in 
the pathological matrix that occludes the artery in coronary restenosis.6 Hyaluronan is 
synthesised by all vertebrates, some Streptococci strains, and viruses. 
Hyaluronan as an essential structural element in the matrix plays an important role 
for tissue architecture by immobilising specific proteins (aggrecan, versican, neuro-
can, brevican, CD44 etc.) in desired locations within the body. Furthermore, hyalu-
ronan is involved in many (patho)physiological processes, like reproduction, cell 
growth and migration as well as tumour spread. Increased levels of hyaluronan are 
observed during morphogenesis, embryonic development, wound healing and in-
flammation.5,7 The function of HA may be partly regulated dependent on its chain 
length, e.g. angiogenesis is presumably induced by small HA oligosaccharides, 
whereas high molecular weight HA exerts inhibitory effects.8 
Cell behaviour like migration etc. is affected by the interaction of hyaluronic acid with 
a variety of receptors and binding proteins on the surface of cells.7,9 The most studied 
hyaluronan receptor to date is CD44 (lymphocyte homing receptor). Several other 
hyaluronan binding proteins have been identified including the RHAMM (receptor for 
hyaluronan which mediates motility), ICAM-1 (intercellular adhesion molecule-1) and 
the LEC receptor (Liver Endothelial Cell clearance receptor).5,6 
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1.2 Hyaluronidases 
1.2.1 History and occurrence 
Hyaluronidase was first identified in an extract of mammalian testes and other tissues 
as a ‘spreading factor’ that facilitated diffusion of antiviral vaccines, dyes and toxins 
injected subcutaneously.10 After the first isolation of hyaluronan by Meyer et al.1 and 
the identification of a HA degrading enzyme in bacteria,11 it could be shown that the 
mammalian spreading factor was also an enzyme degrading hyaluronan.12 Similar 
hyaluronidase-like enzymes were detected and/or isolated from a large number of 
tissues, e.g. liver, kidney, spleen, testes, uterus, placenta, from the venom of snakes, 
lizards, fish, bees, wasps, scorpions, spiders as well as from some bacteria, fungi 
and invertebrate animals. The isolated hyaluronidases differ in their molecular 
weight, substrate specificity and pH optima.13-15 Although ubiquitously found, hyal-
uronidases are not well characterised and are a group of disregarded enzymes due 
to difficult purification and lack of scientific interest over a large period of time. 
1.2.2 Classification of hyaluronidases 
The first classification scheme for hyaluronidases was established in 1971 by K. 
Meyer. According to their catalytic mechanism, the hyaluronidases are grouped into 
three main families (Figure 1.2).16 
The first group of hyaluronidases are the hyaluronate 4-glycanohydrolases (EC 
3.2.1.35) degrading hyaluronan by cleavage of the β-1,4-glycosidic bond to the tet-
rasaccharide as the main product. As a special characteristic, these enzymes also 
catalyse transglycosylation reactions.17,18 The best known enzymes are the testicular, 
the lysosomal and the bee venom hyaluronidase. 
Introduction 
 
 4
O
OH
OH
COOH
HO
O
OH
NHCOCH3
CH2OH
O
O
OH
OH
COOH
O
OH
NHCOCH3
CH2OH
OO O
n = 20 - 12 500
O
OH
OH
OH
COOH
O
OH
NHCOCH3
CH2OH
O
O
OH
OH
COOH
O
OH
OH
NHCOCH3
CH2OH
OO
bovine
testicular
hyaluronidase
EC  3.2.1.35
O
OH
NHCOCH3
OH
CH2OH
O
OH
OH
COOH
O
OH
NHCOCH3
CH2OH
OO O
O OH
OH
OH
COOHleech
hyaluronidase
EC  3.2.1.36
O
OH
OH
OH
COOH
O
OH
OH
NHCOCH3
CH2OH
O
O
OH
OH
COOH
O
OH
OH
NHCOCH3
CH2OH
O
+
bacterial
hyaluronidase
EC  4.2.2.1
hyaluronic acid
H
 
Figure 1.2. Classification of hyaluronidases according to Meyer.16 
The second type is represented by hyaluronidases from leeches and from hook-
worms. These enzymes are hyaluronate 3-glycanohydrolases (EC 3.2.1.36) which 
degrade HA by cleavage of the β-1,3-glycosidic bond. The main product of this reac-
tion is a tetrasaccharide, too. 
The third group, the bacterial hyaluronidases (EC 4.2.2.1) are actually hyaluronate 
lyases. These enzymes degrade hyaluronan by a β-elimination reaction to yield the 
unsaturated disaccharide 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic 
acid)-D-glucose as main product.15,16,19  
As an alternative to the classification according to Meyer, hyaluronidases are divided 
in two main families – the hyaluronidases from eukaryotes and from prokaryotes – 
according to amino acid sequence homology.13,20  
1.2.3 Hyaluronidases from eukaryotes 
In the last years, many human hyaluronidase genes located on human chromosomes 
3p21.3 and 7q31.3.20 were identified and the corresponding proteins were expressed 
in different cell lines. Several isoforms (Hyal1, Hyal2, Hyal3, Hyal4 and PH-
20/Spam1) sharing about 40 % amino acid sequence identity have been found. The 
human testicular hyaluronidase, PH-20 protein, was first expressed by Gmachl et 
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al.21 and is essential for penetration of the hyaluronan-rich cumulus mass that sur-
rounds the oocyte and for fertilisation.22 It is a multifunctional protein with a separate 
domain that binds to the zona pellucida.23 Hyal1 and Hyal2 are found in most tissues 
and body fluids and are believed to act in succession on degrading hyaluronan. 
Hyal2, either anchored to the plasma membrane by a glycosylphosphatidylinositol 
link or occurring in a soluble form, cleaves HA to a product of approximately 20 kDa, 
whereas Hyal1, a lysosomal as well as a plasma enzyme, produces small oligosac-
charides with tetrasaccharides as major products. 
Mutations in the gene hyal1 cause a newly described lysosomal disorder, mucopoly-
saccharidosis IX.24,25 Furthermore, Hyal1 and Hyal2 appear to play a role in tumour 
formation. Hyal1 is a candidate tumour suppressor gene product, deleted in many 
tobacco-related lung tumours.26,27 Hyal2 might share an oncogenic and a tumour 
suppressor gene function. At the one hand, overexpression of Hyal2 accelerates tu-
mour formation of murine astrocytoma cells28 and on the other hand, Hyal2 seems to 
accelerate apoptosis.29 Additionally, a distinct influence of the size of HA degradation 
products on proliferation and, to a lesser extent, on migration could be assumed in 
vitro,8 often referred to as angiogenic switch. In the beginning of tumour formation, 
high molecular weight HA is necessary to provide the flow of nutrients at the primary 
site and subsequently, intermediate HA fragments produced by Hyal2 induce angio-
genesis.30 
Very little is known about Hyal3 found in testis and bone marrow and about Hyal4 
which appears to be a chondroitinase.31 All known hyaluronidases are active at acidic 
pH, consistent with a lysosomal location, except PH-20 which also exhibits activity at 
neutral pH. All of these enzymes were barely investigated up to now15 due to prob-
lems on isolation, purification and activity assays and to their instability. 
By contrast, the bovine testicular hyaluronidase (BTH, bovine PH-20 protein) as well 
known representative of the mammalian hyaluronidases has been used in several 
medical fields for many years, e.g. orthopaedia, ophthalmology and internal medi-
cine.32,33 It is an endo-glycanohydrolase that cleaves the β-1,4 glycosidic bond of 
hyaluronan. In addition to hyaluronic acid, BTH degrades chondroitin and chondroitin 
4- and 6-sulfate, which are structurally related to HA. By using ion-spray mass spec-
trometry, tetrasaccharide and saturated disaccharide fragments could be identified as 
major and as smallest hydrolysis products, respectively.18 The pH optimum of hyal-
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uronidase activity is dependent on the mostly heterogeneous enzyme composition of 
the BTH preparations,34,35 the used substrate, the hyaluronidase assay and the 
incubation conditions.16,34,36,37 
In addition to hydrolase activity, the bovine testicular hyaluronidase exhibits transgly-
cosylase activity if oligosaccharides with 6 to 12 monomer units are available, leading 
to saturated HA oligosaccharides with N-acetylglucosamine at the reducing end.17 
Transglycosylation reactions are dependent on the pH value and the salt content of 
the incubation buffer. The optimal pH value for hydrolase activity is about 4-5, 
whereas pH 7 appears to be optimal for transglycosylation reactions. In the presence 
of NaCl, transglycosylase activity is nearly completely inhibited at concentrations 
higher than 0.5 M.38 
Bee venom hyaluronidase (BVH) is a member of the hyaluronate 4-glycanohy-
drolases (EC 3.2.1.35) like the bovine testicular hyaluronidase. The sequence iden-
tity between mammalian hyaluronidases and bee venom hyaluronidase amounts to 
ca. 30 %. BVH lacks a C-terminal domain of ca. 120-150 amino acid residues pre-
sent in the human and bovine hyaluronidases.39 In 2000, the crystal structure of the 
bee venom hyaluronidase in complex with a HA–based tetrasaccharide was eluci-
dated by Markovic-Housley et al.40 The analysis of the crystal structure reveals an 
unusual overall fold, a (β/α)7 barrel instead of a regular (β/α)8 barrel. The HA binding 
site is situated at the C-terminal end of the β barrel and is lined with many conserved 
amino acids, e.g. both catalytic amino acids Asp111 and Glu113 along with Arg116 
and Arg244 etc. Similar folds were identified for other carbohydrate degrading en-
zymes with a regular (β/α)8 barrel fold  like β-amylase from soybean,41 β-glucuroni-
dase42 etc. With respect to the active site architecture, similarity with BVH was only 
observed for the bacterial chitinase A.43 In particular, the catalytic acids and several 
aromatic residues are located at spatially equivalent positions.40,44  
Due to the co-crystallised HA tetrasaccharide fragment, the catalytic mechanism of 
HA degradation could be elucidated. In general, glycosidases act via a double or a 
single nucleophilic displacement mechanism which results in either retention or in-
version of the configuration of the anomeric carbon atom.44,45 In both cases, the 
glycosidic bond to be cleaved is positioned between two carboxylates, one acting as 
acid/base and the other originally suggested as nucleophile. In the crystal structure of 
BVH, Glu113 appears to be the catalytic acid since it forms a hydrogen bond (2.6 Å) 
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with the the glycosidic bond oxygen O1 of N-acetylglucosamine in subsite -1*. The 
proximate Asp111 seems to keep Glu113 in proper orientation for catalysis via a 
short hydrogen bond between both carboxylates, but is not in an adequate spatial 
position to act as enzymatic nucleophile. Therefore a substrate-assisted mechanism 
is proposed. The N-acetylglucosamine in subsite -1 (1) is distorted to a 4,1C boat 
conformation (Figure 1.3) so that the N-acetyl group of the residue can attack the 
anomeric carbon atom forming a covalent oxazolinium ion intermediate (2). In a 
probably concerted action, Glu113 donates the proton to release the cleaved sugar 
residue. The ionic intermediate is hydrolysed to the product 3 with retention of the 
configuration at C1 of the N-acetylglucosamine at the reducing end.44 A very similar 
mechanism has been postulated for retaining β glycosyl hydrolases of family 18 on 
basis of structural data47-49 as well as theoretical calculations.50  
O
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Figure 1.3. Double-displacement substrate assisted mechanism of bee venom hyaluronidase. The 
saccharide in subsite –1 (1) binds in boat conformation, and catalysis is proposed to occur via a for-
mation of a covalent oxazolinium ion intermediate 2 to the product 3. Adapted from reference 44. 
BVH is a major allergen of bee venom, and knowledge of the structural determinants 
responsible for the allergenic potency is expected to lead to clinical implications. 
1.2.4 Hyaluronidases from prokaryotes 
To date, the amino acid sequences of a variety of hyaluronidases from prokaryotes 
have been decoded.51 The best known and characterised bacterial hyaluronidases 
are Streptococcus pneumoniae and S. agalactiae hyaluronate lyases.19,52,53 Both en-
zymes degrade hyaluronic acid at the β-1,4-glycosidic linkage between D-glucuronic 
acid and N-acetyl-D-glucosamine. The product of this elimination reaction is the un-
                                            
*
 By convention, the sugar residue subsites are labelled from -n to +n, with -n at the non-reducing end 
and +n at the reducing end of the substrate. Cleavage occurs between the -1 and +1 subsites.46 
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saturated disaccharide 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic 
acid)-D-glucose.15,16,19,54 Recently, the 3D structures of S. pneumoniae and S. 
agalactiae strain 3502 hyaluronidases were elucidated by X-ray analyses.52,53,55,56 
The active site of S. pneumoniae hyaluronidase (hylSpn) is composed of two main 
parts, a catalytic triad responsible for the substrate degradation and an aromatic 
patch responsible for the selection and the positioning of cleavage sites on the poly-
meric substrate.56 The residues that form the aromatic patch of the enzyme are 
Trp291, Trp292 and Phe343, those of the catalytic triad are His399, Tyr408 and 
Asn349. 
Based on the crystal structure and mechanistical studies, the mechanism of the eli-
mination reaction was revealed.52,53,55,57 In the first step, the positively charged cleft 
of the enzyme attracts and binds the negatively charged substrate chain. Three di-
saccharide units can be accommodated into the cleft (see Figure 1.4, only two, HA1 
and HA2, of the three units are drawn). In the second step, the aromatic patch of the 
active site interacts with the substrate chain and anchors it in optimal position. In the 
third step, the glucuronic acid of HA1 is deprotonated at C5 by His399 (Figure 1.4). 
At the same time, Tyr408 donates a proton to the glycosidic oxygen connecting D-
glucuronic acid of HA1 and N-acetyl-D-glucosamine of HA2. The glycosidic bond is 
cleaved by 1,2-elimination forming the double bond of the unsaturated final product 
(fourth step). Finally (fifth step), the catalytic triad is regenerated: His399 is deproto-
nated and Tyr408 is protonated by a water molecule.  
This mechanism could be strongly supported by elucidation of 3D structures of the 
native enzyme hylSpn in complex with hyaluronan-based fragments of various 
lengths.58 Furthermore, both hyaluronidases also cleave chondroitin and chondroitin 
sulfate (specific sulfation pattern provided)19 which could also be analysed in detail 
by a X-ray structure of hylSpn in complex with chondroitin and chondroitin sulfate 
disaccharides.59  
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Figure 1.4. Mechanism of hyaluronan degradation by S. pneumoniae hyaluronate lyase according to 
Li et al.56 Schematic representation of hyaluronic acid with HA1 and HA2 as disaccharide units and the 
position of the side chains of Tyr408, His399 and Asn349 relative to the substrate. 
The S. agalactiae strain 4755 hyaluronate lyase (hylB4755) shows sequence identities 
of 98 % with the homologous enzyme of S. agalactiae strain 3502 (hylB3502)60,61 and 
of 53 % with S. pneumoniae hyaluronidase. In contrast to the crystal structure of 
hylSpn,56 the hylB3502 structure consists of three instead of two distinct structural do-
mains (see Figure 1.5).55 In particular, it contains an additional βI-domain preceding 
the α-domain at the N-terminus of the protein. The α-domain, the short 10-residue 
linker after it, and the following β-domain (βI in hylSpn, βII in hylB3502) are present in 
both lyases. 
In general, both hyaluronidases are highly similar with respect to the overall archi-
tecture of the structures and to the spatial arrangement of the active site residues, 
but major differences occur at the end of the α-domain, especially in the region that 
includes the catalytic cleft. In the hylB3502 structure, rotation of the α- with respect to 
the βII-domain by a small angle leads to a cleft which is about 7.3 Å wider than in the 
hylSpn structure (Figure 1.5).55 As a consequence, the spatial positions of the 
catalytically active amino acids Tyr488, His479 and Asn429 (Tyr408, His399 and 
Asn349 in hylSpn) are significantly different.55 Nevertheless, the catalytic mecha-
nisms of hylB3502 and hylSpn are probably identical since the observed more open 
conformation of hylB3502 might result from the crystallisation conditions. 
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Figure 1.5. Superposition of αI-domains of crystal structures of hylSpn (green) and hylB3502 (red).  
Bacterial hyaluronate lyase is a virulence factor which facilitates the spreading of the 
microorganisms by degradation of hyaluronan. Human infection by S. agalactiae is 
one of the major causes of meningitis and septicaemia and many other serious dis-
eases leading to death in neonates.62,63 To study the role of hyaluronan and 
hyaluronidases in bacterial infection, the design and development of hyaluronate 
lyase inhibitors become more and more important.  
1.3 Medical applications of hyaluronan and hyaluronidases 
Due to the high water-binding capacity of hyaluronan and the viscoelasticity of hyalu-
ronan solutions, it is suitable for various therapeutical purposes. Probably in the late 
1950s hyaluronan was applied for the first time to humans, namely as vitreous hu-
mour supplement/replacement during eye surgery, an application which has proven 
of value up to now (e.g., in cataract surgery).64 Sodium hyaluronate and a covalently 
cross-linked form of hyaluronan are successfully used for the treatment of os-
teoarthritis.65 Anabolic effects of HA on degraded articular cartilages suppress their 
degeneration.66 HA normalises the properties of synovial fluids67 and reduces the 
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perception of pain.68,69 Additionally, in many clinical situations, a rapid increase of 
hyaluronan levels is observed, e.g. in shock incidents, septicaemia and in burn pa-
tients.13,14,25 
By cleaving hyaluronan in tissues, hyaluronidases increase the membrane perme-
ability, reduce the viscosity and promote the diffusion of injected fluids; these phe-
nomena are referred to as spreading effect of hyaluronidases. Thus, these enzymes 
could be used therapeutically to increase the speed of absorption, to facilitate re-
sorption of excess fluids, to improve the effectiveness of local anaesthesia and to 
prevent tissue destruction resulting from subcutaneous and intramuscular injection of 
fluids.14,32 Hyaluronidases, especially BTH preparations, are indeed widely used in 
many fields like orthopaedia, surgery, ophthalmology, internal medicine, oncology, 
dermatology, gynaecology etc.6,32,70,71 Due to depleted supplies of pharmaceutical 
BTH preparations, a number of cases of iatrogenic strabismus have been observed 
after cataract surgeries.72 With respect to this shortage, pharmaceutical preparations 
with bacterial34 or ovine hyaluronidase73 are suggested as replacement of BTH. 
Hyaluronidase has been investigated as an additive to chemotherapeutic drugs for 
augmentation of the anticancer effect.33,36,74,75 There is evidence that hyaluronidase 
may have intrinsic anticancer effects and can suppress tumour progression, how-
ever, the findings are rather inconsistent. The specific function of Hyal1 and Hyal2 in 
different tumours is still contradictory, and also the angiogenic effect of HA fragments 
must be taken into consideration. Furthermore, it was reported, that treatment with 
hyaluronidase blocks lymph node invasion by tumour cells in an animal model of T 
cell lymphoma.76 
Sperm hyaluronidase plays an important role for successful fertilisation in most 
mammals, including humans.77,78 
1.4 Inhibitors of hyaluronidases 
To prove and to further investigate the role and the importance of hyaluronan and 
hyaluronidase in physiological and pathophysiological processes, selective and po-
tent inhibitors are required. The first studies on hyaluronidase inhibitors were pub-
lished 50 years ago.79-81 In 1951, Meyer et al. reported on hyaluronidase inhibition by 
iron, copper and zinc salts, heparin, polyphenols and flavonoids.79 Due to the struc-
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tural similarity of heparin and heparan sulfate to hyaluronic acid, these oligosaccha-
rides were investigated as inhibitors of hyaluronidase, but the inhibition was achieved 
only at concentrations much higher than physiological levels.32,82-84 Asada et al. 
examined the effect of various types of alginic acid consisting of L-glucuronic acids 
and D-mannuronic acids on the bovine testicular hyaluronidase.85 The inhibition by 
sodium alginate was dependent on the molecular weight – the higher the molecular 
weight, the stronger the inhibition. Based on these results, Toida et al. investigated 
O-sulfated glycosaminoglycans of which the fully sulfated compounds showed the 
highest inhibitory effect.86  
Also some flavones and flavone analogues like apigenin and kaempferol inhibit hyal-
uronidase,87-90 but not selectively and only at millimolar concentrations.91 Further 
compounds with likewise weak inhibitory activity were detected, e.g. aescin, disodium 
cromoglycate, tranilast, traxanox, hederagenin, norlignane, urolithin B etc.87,92-95 Re-
cently, vitamin C,96 L-arginine derivatives97 and fatty acids98 were reported to inhibit a 
streptococcal hyaluronidase with IC50 values at (sub)millimolar concentration. 
In general, the published data (% inhibition and IC50 values) of these compounds are 
not comparable among each other because of differences in the applied test systems 
(e.g. incubation condition, enzymes and substrate concentrations). Due to the im-
portance of hyaluronan and hyaluronidase in many clinical applications, selective and 
potent inhibitors are worthwhile but it is apparent that their systematic development 
has barely begun. In this respect computer-aided molecular design methods could 
make a significant contribution. 
1.5 Virtual screening and structure-based ligand design 
One of the key elements in a drug development project is the discovery of new and 
innovative lead compounds. In the last years, the pharmaceutical industry has in-
vested much effort to establish compound libraries that can be searched for leads. 
On the one hand, high-throughput facilities with in-house compound stocks were de-
veloped to generate biological activity data for a variety of targets in a very short pe-
riod of time. Despite the great enthusiasm in the early stage, the use of high-
throughput screening (HTS) has often resulted in low success rates for the conver-
sion of apparent HTS hits into lead compounds due to many problems like false posi-
Introduction 
 
 13
tives, non specific binding, low solubility etc.99 On the other hand, virtual screening 
has emerged as an alternative and complementary approach to experimental HTS. 
This methodology subsumes a large repertory of computational tools for the selection 
of potentially active and bioavailable compounds from libraries. Fast filter approaches 
and coarse molecular similarity criteria as well as sophisticated docking and scoring 
techniques are applied in this field.100 
Starting point of these theoretical methods is a virtual compound library containing in 
principle any imaginable molecule. Preferentially, due to fast substance acquisition 
and easy validation of initial computer hits, compound collections of in-house or 
commercially available molecules are initially screened. The Available Chemical Di-
rectory (ACD),101 the LeadQuest® libraries,102 the ChemStar Library103 are examples 
of libraries with commercially available compounds. The World Drug Index104 and the 
MDL Drug Data Report105 databases, which are compiled from drugs launched or 
under development, are frequently used in virtual screening approaches, too. Further 
libraries are designed by means of building blocks of combinatorial chemistry. 
Reasonably, applying fast filter criteria, compounds with undesired physicochemical 
properties are eliminated at the beginning of a virtual screening approach. Since in-
sufficient pharmacokinetic properties (ADMET: absorption, distribution, metabolism, 
excretion, and toxicity) of the proposed drug candidates have led or still lead to the 
termination of many drug development projects,106 increasing efforts are made to 
define structural requirements which molecules have to meet for further consideration 
as potential drug. Apart from filters like molecular weight ranges, the total number of 
H-bond acceptor and donor groups,107 neural networks are applied to discriminate 
between drug-like and non drug-like molecules on basis of structural patterns.108,109 
Nowadays, the application of virtual screening approaches accelerates the discovery 
of new lead compounds and their structural optimisation with respect to affinity and 
pharmacological properties. The general kind of approach depends on the availability 
of a three-dimensional (3D) structure of the biological target. If present, structure-
based virtual screening is possible, otherwise only ligand-based design methods may 
be applied.110  
Structure-based approaches are to design compounds which spatially fit to a binding 
site on the macromolecule by forming electrostatic, steric and hydrophobic interac-
tions. Two general cases of searching for such biologically active molecules may be 
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discriminated: molecular database mining and de novo ligand design combined with 
fast automated docking. Prerequisite of all virtual screening methods is the detailed 
knowledge about the localisation and the geometry of the binding site, mostly de-
duced from X-ray structures with co-crystallised natural substrates or synthetic or-
ganic ligands. 
Until now, several screening and de novo design programmes like CAVEAT,111 
TOPAS,112 LeapFrog113 and LUDI114 have been described enabling the rational de-
sign of new ligands based on the 3D structure of a target protein.100,115 As initial step 
most of these programmes perform a detailed analysis of the amino acid residues 
forming the binding pocket and extract the spatial binding features which potential 
ligands have to meet. These favourable interaction sites are then converted into a 
complex pharmacophoric model of the active site of the target. Large databases of 
small molecules can be computationally screened for fit with this model, resulting in 
the identification of complementary ligands in terms of geometrical and physico-
chemical properties. Putative screening hits are selected by a scoring function 
roughly predicting affinity. The scoring of the proposed ligand pose (target-bound 
conformation and orientation of the screened ligand) approximates the interaction 
between the ligand and the amino acid residues of the binding pocket.116,117 Any ra-
tional design approach includes several design cycles with appropriate structural 
modifications, syntheses and testing of the new candidate structures, aiming at 
ligands with improved binding affinities. 
In many cases, these approaches are accompanied by fast automated post-dock-
ing.100 Prerequisites of these automated methods are the knowledge of the 3D 
coordinates of the target protein and the candidate molecules as well as a scoring 
function for the accurate prediction of binding affinities. Programmes which vary the 
relative orientation and the conformation of the ligand in the binding site are classified 
as flexible docking programmes. However, most methods still neglect protein flexibil-
ity by docking into a rigid active site. A variety of protein-ligand docking algorithms 
have been developed like FlexX,118 AutoDock,119 DOCK120 etc. Exemplarily, the 
principles of FlexX are outlined very briefly. Its incremental construction algorithm 
handles the conformational freedom of the ligands by dividing them into smaller 
fragments at their rotatable bonds and reassembling these fragments within the 
binding site. First, the base fragment, a rather rigid ligand fragment, is favourably 
placed into the binding site in terms of directed hydrophobic and/or hydrogen bond 
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interactions. Subsequently, by creating a set of high-scoring partial placements, the 
remaining fragments are successively connected to the base fragments. The crucial 
issue of FlexX and all other flexible docking programmes is a prediction of a native-
like binding mode in combination with an accurate scoring of the putative binding af-
finity. The evaluation of the docking performance of several flexible docking algorithm 
revealed significant differences in docking and scoring quality and a dependence of 
the resulting best performing algorithm on the particular polarity of the active site.121 
Ligand-based methods are applied if no structural information about the target and its 
ligand binding site, i.e. no crystal structure or no reliable homology model, is avail-
able. Based on the analysis of ligands with known biological activity, these methods 
include the design of pharmacophoric models122 by, e.g., the active analogue ap-
proach,123 the analysis of quantitative structure-activity relationships (classical 
QSAR) and 3D-QSAR.124 Also pseudoreceptor models for screening are employed to 
discover lead compounds and/or to optimise known ligands.110 
By now, computer aided drug design has evolved into a substantial part of the drug 
discovery process. The application of virtual screening approaches accelerates the 
decision-making process in drug discovery and will become an indispensable part of 
future medicinal chemistry.100 
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Chapter 2 Objectives 
Potent and selective hyaluronidase inhibitors are required as pharmacological tools 
to study the physiological and pathophysiological role of hyaluronan and hyaluroni-
dases. Additionally, such compounds are of potential therapeutic value for the treat-
ment of a variety of diseases, e.g. arthroses, cancer, or bacterial infections. Nowa-
days, the application of computer-aided drug design accelerates the discovery of new 
lead compounds and their structural optimisation with respect to affinity and pharma-
cological properties. As potent and selective inhibitors of bacterial and mammalian 
hyaluronidases are not known to date, the main goal of this thesis was the prediction 
and selection of lead-like structures by de novo ligand design and virtual screening of 
generated compound libraries. The inhibitory effects of the suggested molecules 
were investigated on S. agalactiae hyaluronate lyase and on the bovine testicular 
hyaluronidase as main representatives of the bacterial and mammalian enzymes, 
respectively. 
As first project, a de novo design approach was intended to discover inhibitors of S. 
agalactiae strain 4755 hyaluronan lyase based on the elucidation of the three-dimen-
sional structures of two other bacterial hyaluronidases.† This project comprises the 
development of a homology model of S. agalactiae strain 4755 hyaluronan lyase by 
means of the programme MODELLER and the subsequent de novo ligand genera-
tion using the structure-based design software LUDI.  
Prerequisites of de novo design are databases with three-dimensional (3D), pre-
dominantly drug-like structures. In the second project, starting from the ChemACX 
selection of commercially available compounds, a 3D database should be generated 
by elimination of putatively non drug-like compounds. In comparison to LeadQuest® 
libraries of drug-like, synthetically feasible screening compounds, the resulting 
ChemACXF database should be analysed with respect to suitability for virtual 
screening purposes. 
                                            
†
 The synthesis and pharmacological investigations of the proposed molecules have been carried out 
by Sunnhild Salmen as part of her PhD project, Universität Regensburg, 2003. 
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The third project aimed at structure-based ligand design for inhibitors of mammalian 
hyaluronidase. A homology model of the bovine testicular hyaluronidase was gener-
ated by means of MODELLER on the basis of crystal structures of the bee venom 
hyaluronidase. Subsequent LUDI calculations with this enzyme model should result 
in first lead compounds. Further BTH ligands should be derived by an active ana-
logue-like approach starting from the superposition of the binding site of bovine tes-
ticular hyaluronidase with similar sites of related chitinases in complex with their in-
hibitors. 
The X-ray structure of S. pneumoniae hyaluronate lyase complexed with L-ascorbic 
acid was recently elucidated. In the fourth, joint project,‡ L-ascorbic acid-6-hexa-
decanoate was investigated as inhibitor of bacterial and bovine hyaluronidase. A 
crystal structure of a complex of S. pneumoniae hyaluronate lyase with the inhibitor 
should lead to more detailed information about the interaction of L-ascorbic acid-6-
hexadecanoate with the amino acids in the active site. In comparison with the bacte-
rial enzyme, flexible docking of L-ascorbic acid-6-hexadecanoate in the bovine tes-
ticular hyaluronidase model should help to develop improved binding models for fur-
ther, more potent and selective hyaluronidase inhibitors. 
In the fifth project, following a published strategy of virtual database screening using 
3D pharmacophores derived from crystal structure complexes, a 3D pharmacophore 
model was derived from the X-ray structure of S. pneumoniae hyaluronate lyase in 
complex with a 2-phenylindole-based inhibitor. By comparison of its binding mode 
and of the 3D pharmacophore with known structure-activity relationships of 2-
phenylindole derivatives, conclusions about the putative binding mode of benzoxa-
zole-2-thione derivatives as bacterial hyaluronidase inhibitors should be derived. 
                                            
‡
 The co-crystallisation experiments have been carried out by Mark J. Jedrzejas (Children's Hospital 
Oakland Research Institute, Oakland, California 94609, USA) and Daniel J. Rigden (National Centre 
of Genetic Resources and Biotechnology, Cenargen/Embrapa, Brasília, D.F. 70770-900, Brazil). 
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Chapter 3 Structure-based design of hyaluronate 
lyase inhibitors 
3.1 Introduction 
Bacterial hyaluronate lyases (EC 4.2.2.1) differ from hyaluronidases from other 
sources by their mode of action. They cleave the β-1,4-glycosidic bond between N-
acetyl-β-D-glucosamine and D-glucuronic acid residues by an elimination reaction 
resulting in unsaturated hexuronic acid residues at the nonreducing ends.1 The 
hyaluronan lyases of pathogenic bacteria are putative virulence factors due to the 
spreading effect in host tissues resulting from the degradation of hyaluronic acid (HA) 
of the extracellular matrix.2 Potent inhibitors of hyaluronan lyases are not known to 
date. Such compounds could be useful in studying the role of hyaluronan and hyalu-
ronidases in bacterial infections and may even be promising with respect to the in-
vestigation of a novel, possibly auxiliary antibacterial therapy. 
Some small compounds like arginine and guanidine derivatives3 and vitamin C4 with 
IC50 values in the range of 150 to 0.150 mM vs. bacterial hyaluronidases have been 
described. For the development of a new class of bacterial hyaluronidase inhibitors, 
the primary goal of the present study was the identification of simple compounds as 
possible lead structures. A crucial issue for improving binding affinity, selectivity or 
bioavailability is the quick synthetic accessibility of relatively simple structures by de-
rivatisation of the lead compound. Until now, several computational methods like 
GROW,5 LEGEND6 and LUDI7,8 have been described enabling the rational design of 
new ligands based on the three-dimensional (3D) structure of a target protein.9,10 As 
initial step most of these programmes perform a detailed analysis of the amino acid 
residues constituting the binding pocket and extract the spatial binding features 
which potential ligands have to meet. These favourable interaction sites are then 
converted into a complex pharmacophoric model of the active site of the enzyme. 
Large databases of small molecules can be computationally screened for fit with this 
model, resulting in the identification of complementary ligands in terms of geometrical 
and physicochemical properties. Putative screening hits are selected via a rough af-
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finity prediction estimated by a scoring function. The scoring of the proposed ligand 
pose (target-bound conformation and orientation of screened ligand) reflects the in-
teraction between the functional moieties on the ligand and the amino acid residues 
of the binding pocket.11,12 Rational design includes several design cycles with 
appropriate structural modifications, synthesis and testing of the new candidate 
structures, aiming at ligands with improved binding affinities. 
As a pilot scheme for hyaluronidase inhibitor design in general, we launched a 
structure-based design programme of S. agalactiae strain 4755 hyaluronate lyase 
(hylB4755) inhibitors using the de novo design software LUDI.7,8 A homology model of 
hylB4755 was derived from the crystal structures of two streptococcal lyases. The 
hylB4755 hyaluronidase shows extensive sequence identity with the homologous tem-
plate enzymes encoded by genes from group B Streptococcus (S. agalactiae) strain 
3502 (hylB3502) and S. pneumoniae (hylSpn). Recently, the X-ray structures of hylSpn 
and hylB3502 were determined.13,14 Additionally, a complex of hylB3502 with a sub-
strate-based HA hexasaccharide could be elucidated by means of X-ray crystallogra-
phy.15 These results reveal the catalytic mode of action, including the identification of 
specific residues involved in the degradation of hyaluronan by hylB3502.15 
In this chapter, the design and identification of first promising leads as micromolar 
inhibitors of S. agalactiae strain 4755 hyaluronate lyase are reported.  
3.2 Results and discussion 
3.2.1 HylB4755 model construction  
Necessary conditions for homology modelling of protein structures are a significant 
similarity of the target and the template sequences and a sequence alignment close 
to reality.16 The sequence identity of the crystallised hyaluronate lyases hylSpn (pdb 
code 1egu)13 and hylB3502 (pdb code 1f1s)14 is 53 % whereas it is even 98 % be-
tween the streptococcal enzymes hylB3502 and hylB4755. With respect to the active 
sites, identities amount to 85 % (hylB4755 vs. hylSpn) and 99 % (hylB4755 vs. hylB3502), 
respectively. Thus, the crystal structures of the streptococcal hyaluronidases hylSpn 
and hylB3502 have provided the first possibility to construct a reliable model of the 
parent bacterial enzyme group B streptococcal hyaluronidase hylB4755.  
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As a first step, a multiple sequence alignment of hylB4755, hylB3502 and hylSpn (see 
Figure 3.1) was generated using ClustalW.17,18 The structurally conserved regions 
(SCR) of both crystal structures could easily be extracted since almost all insertions 
in the hylB3502 sequence occur in the βII-domain surface loop areas.14 Given that the 
primary structures of hylB3502 and hylB4755 are almost identical, the question arose 
whether the X-ray structure of S. agalactiae strain 3502 hyaluronan lyase may be 
directly used as starting point for the structure-based ligand design instead of con-
structing a homology model of the strain 4755 enzyme. 
A detailed analysis after superposition of both available X-ray structures of hyaluro-
nate lyases revealed that the conformation of hylB3502 does not represent a catalyti-
cally active state. In contrast to the crystal structure of hylSpn, the hylB3502 structure 
consists of three instead of two distinct structural domains (see chapter 1, Figure 
1.5).14 In particular, it contains an additional βI-domain preceding the α-domain at the 
N-terminus of the protein. The α-domain, the short 10-residue linker in-between, and 
the following β-domain (βI in hylSpn, βII in hylB3502) are present in both lyases. De-
spite of a high similarity of the whole architecture of the structures and of the spatial 
arrangement of the active site residues, the root mean square (rms) deviation of the 
Cα-atom positions for the whole structures is 2.47 Å. The major difference is ob-
served at the end of the α-domain, especially in the region that includes the catalytic 
cleft. The rotation of the α- with respect to the βII-domain by a small angle around the 
linker in the hylB3502 structure leads to a cleft which is about 7.3 Å wider than in the 
hylSpn structure.14 As a consequence, the spatial positions of the catalytically active 
amino acids Tyr488, His479 and Asn429 (Tyr408, His399 and Asn349 in hylSpn) are 
significantly different.14 
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hylB4755 316 KISDKSGKIIKEVPLSVTASTEDKFTKLLDKWNDVTIGNHVYDTNDSNMQKINQKLDETNAKNIKTIKLD 
hylB3502 228 KISDKSGKIIKEVPLSVTGSPEDNFTKLLDKWNDVTIGNYVYDTNDSNMQKLTQKLDETNGKNIEAIKLD 
hylSpn   150 VIVSKDGKEVKKIPLKILASVKDTYTDRLDDWNGIIAGNQYYDSKNDQMAKLNQELEGKVADSLSSISSQ 
             |         |         |         |         |         |         |          
hylB4755 386 SNHTFLWKDLDNLNNSAQLTATYRRLEDLAKQITNPHSTIYKNEKAIRTVKESLAWLHQNFYNVNKDIEG 
hylB3502 298 SNRTFLWKDLDNLNNSAQLTATYRRLEDLAKQITNPHSTIYKNEKAIRTVKESLAWLHQNFYNVNKDIEG 
hylSpn   220 ADRIYLWEKFSNYKTSANLTATYRKLEEMAKQVTNPSSRYYQDETVVRTVRDSMEWMHKHVYNSEKSIVG 
             |         |         |         |         |         |         |          
hylB4755 456 SANWWDFEIGVPRSITATLALMNNYFTDAEIKTYTDPIEHFVPDAGYFRKTLDNPFKALGGNLVDMGRVK 
hylB3502 368 SANWWDFEIGVPRSITGTLSLMNNYFTDAEIKTYTDPIEHFVPDAEYFRKTLVNPFKALGGNLVDMGRVK 
hylSpn   290 --NWWDYEIGTPRAINNTLSLMKEYFSDEEIKKYTDVIEKFVPDPEHFRKTTDNPFKALGGNLVDMGRVK 
             |         |         |         |         |         |         |          
hylB4755 526 IIEGLLRKDNTIIEKTSHSLKNLFTTATKAEGFYADGSYIDHTNVAYTGAYGNVLIDGLTQLLPIIQETD 
hylB3502 438 IIEGLLRKDNTIIEKTSHSLKNLFTTATKAEGFYADGSYIDHTNVAYTGAYGNVLIDGLTQLLPIIQETD 
hylSpn   358 VIAGLLRKDDQEISSTIRSIEQVFKLVDQGEGFYQDGSYIDHTNVAYTGAYGNVLIDGLSQLLPVIQKTK 
             |         |         |         |         |         |         |          
hylB4755 596 YKISNQELDMVYKWINQSFLPLIVKGELMDMSRGRSISREAASSHAAAVEVLRGFLRLANMSNEERNLDL 
hylB3502 508 YKISNQELDMVYKWINQSFLPLIVKGELMDMSRGRSISREAASSHAAAVEVLRGFLRLANMSNEERNLDL 
hylSpn   428 NPIDKDKMQTMYHWIDKSFAPLLVNGELMDMSRGRSISRANSEGHVAAVEVLRGIHRIADMSEGETKQRL 
             |         |         |         |         |         |         |          
hylB4755 666 KSTIKTIITSNKFYNVFNNLKSYSDIANMNKMLNDSTVATKPLKSNLSTFNSMDRLAYYNAEKDFGFALS 
hylB3502 578 KSTIKAIITSNKFYNVFNNLKSYSDIANMNKLLNDSTVATKPLKSNLSTFNSMDRLAYYNAKKDFGFALS 
hylSpn   498 QSLVKTIVQSDSYYDVFKNLKTYKDISLMQSLLSDAGVASVPRTSYLSAFNKMDKTAMYNAEKGFGFGLS 
             |         |         |         |         |         |         |       
hylB4755 736 LHSKRTLNYEGMNDENTRGWYTGDGMFYLYNSDQSHYSNHFWPTVNPYKMAGTTEKDAKREDTTKEFMSK 
hylB3502 648 LHSKRTLNYEGMNDENTRGWYTGDGMFYIYNSDQSHYSNHLGPTVNPYKMAGTTEKDAKREDTTKEFMSK 
hylSpn   568 LFSSRTLNYEHMNKENKRGWYTSDGMFYLYNGDLSHYSDGYWPTVNPYKMPGTTETDAKRADS------- 
             |         |         |         |         |         |         |       
hylB4755 806 HSKDAKEKTGQVTGTSDFVGSVKLNDHFALAAMDFTNWDRTLTAQKGWVILNDKIVFLGSNIKNTNGIGN 
hylB3502 718 HSKDAKEKTGQVTGTSDFVGSVKLNDHFALAAMDFTNWDRTLTAQKGWVILNDKIVFLGSNIKNTNGIGN 
hylSpn   631 D-------TGKVLP-SAFVGTSKLDDANATATMDFTNWNQTLTAHKSWFMLKDKIAFLGSNIQNTS-TDT 
             |         |         |         |         |         |         |       
hylB4755 876 VSTTIDQRKDDSKTPYTTYVNGKTIDLKQASSQQFTDTKSVFLESKEPGRNIGYIFFKNSTIDIERKEQT 
hylB3502 788 VSTTIDQRKDDSKTPYTTYVNGKTIDLKQASSQQFTDTKSVFLESKEPGRNIGYIFFKNSTIDIERKEQT 
hylSpn   692 AATTIDQRKLESSNPYKVYVNDKEASLTEQE-KDYPETQSVFLESSDSKKNIGYFFFKKSSISMSKALQK 
             |         |         |         |         |         |         |       
hylB4755 946 GTWNSINRTSKNTSIVSNPFITISQKHDNKGDSYGYMMVPNIDRTSFDKLANSKEVELLENSSKQQVIYD 
hylB3502 858 GTWNSINRTSKNTSIVSNPFITISQKHDNKGDSYGYMMVPNIDRTSFDKLANSKEVELLENSSKQQVIYD 
hylSpn   761 GAWKDIN-EGQSDKEVENEFLTISQAHKQNGDSYGYMLIPNVDRATFNQMIKELESSLIENNETLQSVYD 
             |         |         |         |         |         |         |       
hylB47551016 KNSQTWAVIKHDNQESLINNQFKMNKAGLYLVQKVGNDYQNVYYQPQTMTKTDQLAI----- 
hylB3502 928 KNSQTWAVIKHDNQESLINNQFKMNKAGLYLVQKVGNDYQNVYYQPQTMTKTDQLAI----- 
hylSpn   830 AKQGVWGIVKYDDSVSTISNQFQVLKRGVYTIRKEGDEYKIAYYNPETQESAPDQEVFKKQH 
Figure 3.1. Sequence alignment of hylB4755, hylB3502 and hylSpn as the basis of homology 
modelling. The SCRs -helices 1-7 (blue), -helices 8-13 (green) and -strands (purple) are 
highlighted. All 26 amino acids of the active sites are coloured in red. 
Structure-based design of hyaluronate lyase inhibitors 
 
29 
(For a detailed description of the postulated mechanism of HA degradation see 
chapter 1, Figure 1.4.) This fact can be illustrated by measuring the distances 
between specific atoms of the side chains of these residues and the complexed 
substrate-based HA hexasaccharide inside the active site of hylSpn19 and hylB3502 
after superposition of the α-domains of both hyaluronidases. The distances between 
the oxygen atom of the Tyr408/Tyr488 sidechains and the oxygen atom O4 of the 
glycosidic bond to be cleaved are 2.97 Å and 6.64 Å for hylSpn and hylB3502, 
respectively. A comparable result is obtained for the distances between the ε-
nitrogen atom of His399/His479 and the carbon atom C5 of the glucuronic acid in 
subsite§ +1 with 3.78 Å and 7.0 Å for hylSpn and hylB3502, respectively. Mello et al. 
obtained similar results by analysing the complex of a substrate-based HA 
hexasaccharide and hylB3502 with distances of 6.14 Å for O4 – Tyr488 OH and 5.68 Å 
for C5 – His479 Nε, respectively.15 As a consequence, with respect to the substrate 
HA, the spatial arrangement of the catalytic residues Tyr488 and His479 in the 
hylB3502 structure is not optimal for catalysis. Therefore, a homology model of hylB4755 
based on the X-ray structures of hylSpn in terms of optimal geometry and hylB3502 in 
terms of structural similarity was envisaged. 
To extract the SCRs from both X-ray structures, a superposition of all secondary 
structure elements was performed for the α- and βII-domains separately since the 
within-domain similarities are very high.14 The α-domains of both lyases were frag-
mented into two parts; the first one comprises the α-helices 1 to 7 and the second 
one the α-helices 8 to 13 because visual inspection of the superimposed structures 
revealed a slight rotation of both parts within the α-domain of hylB3502 compared to 
hylSpn. The rms deviation for all backbone atoms of the α-helices 1 to 7 is 0.59 Å 
whereas it is 1.08 Å for the α-helices 8 to 13. Both values indicate a very high simi-
larity of both α-domains. The superposition of all β-sheets of the βII-domains also 
resulted in an excellent overlap with a rms deviation of 0.65 Å. 
                                            
§
 By convention, the sugar residue subsites are labelled from -n to +n, with -n at the non-reducing end 
and +n at the reducing end of the substrate. Cleavage occurs between the -1 and +1 subsites.20 
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Hence, the α- and βII-domains of hylB3502 separately superimposed with the respec-
tive domains of hylSpn were extracted to form the framework of the SCRs of the 
hylB4755 model. The missing linker was inserted from the hylB3502 structure and fitted 
onto the anchor residues at the end of the α-domain and at the beginning of the βII-
domain of the framework model. Subsequently, the fifteen different amino acids of 
the hylB3502 primary structure were mutated into the respective amino acids of 
hylB4755. Due to the very high homology of the amino acid sequences, the overall 
model closely resembles the structure of the templates. The calculated rms deviation 
of all Cα atoms amounts to 1.02 Å for the hylB4755 model vs. the hylSpn crystal 
structure. The energy minimised model of hylB4755 is shown in Figure 3.2. 
3.2.2 Search for molecular fragments as ligands of bacterial hyaluroni-
dase using the computer programme LUDI 
Using the de novo design programme LUDI, small and fairly rigid molecules were 
retrieved from a 3D structure database by positioning them into the protein-binding 
site. For each successfully docked ligand, LUDI estimates the expected binding affin-
 
Figure 3.2. Schematic representation of hylB4755 model. α-helices, β-sheets and loop regions are 
coloured in purple, yellow and cyan, respectively. 
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ity by an empirical scoring function.20 Based on the homology model of hylB4755, we 
screened entries from the LeadQuest® databases Vol. 1&221 with LUDI. Prior to the 
search, the molecules from the LeadQuest® databases were processed using CON-
VERTER22 to generate reasonable 3D structures. Using standard parameters for 
LUDI calculations, all 3D structures are treated as rigid bodies independent of the 
existence of rotatable bonds. 
This 3D database was reprocessed by GENFRA, a module of the LUDI programme 
suite, to classify all molecules in terms of their hydrogen bonding and lipophilic prop-
erties and to calculate the fraction of solvent-accessible surface of their functional 
groups. Appropriate fit centres were assigned to all functional moieties of the ligands 
to be screened and saved in a supplementary database by GENFRA. Subsequently, 
for all functional groups exposed to the active site of the enzyme, putative interaction 
sites in space were generated by LUDI according to rules which have been derived 
from composite crystal-field environments compiled with appropriate crystal data of 
small molecules (Cambridge Structural Database).7 The programme tries to fit each 
database molecule onto these interaction sites in the pre-defined binding pocket. The 
centre of this pocket was defined as the arithmetic mean of all atom positions of the 
active site amino acids Arg409, Trp460, Tyr576, Val579 and Arg634. All residues 
within a sphere of 5 Å around this centre were included into the LUDI calculation. 
This active site of hylB4755 is shown together with the pre-calculated interaction sites 
in Figure 3.3. 
After four days calculation time, 122 hits were retrieved by the described procedure 
and were ranked on a relative scale in terms of their expected binding affinity using 
the scoring function described by Böhm.20 Since neither ligand nor protein flexibility is 
taken into account when using the parameters described above, a subsequent LUDI 
run with slightly altered parameters was accomplished. To allow for a larger search 
space and for more interaction possibilities, the radius of the sphere was enlarged to 
8 Å and one rotatable bond at a time was treated flexible. In order to retrieve new 
compounds, the hit database was combined with the original LUDI database as sup-
plied by Accelrys. 
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Figure 3.3. Interaction sites generated by LUDI with sphere radius of 5 Å (yellow, lipophilic sites; red, 
hydrogen bond acceptors) inside the active site of the hylB4755 model. Compound 2 (green) retrieved 
from the combined databases with the highest scoring value is fitted onto these interaction sites. 
A LUDI run with these adapted parameters on the whole LeadQuest® database 
would have taken far too long to be completed in a reasonable time. 212 structures 
from the combined database were retrieved by LUDI and ranked in terms of their ex-
pected binding affinity if the predicted Ki value was lower than 1 mM (LUDI score 
higher than 300). 
In parallel to these investigations, an additional database with commercially available 
compounds has been constructed starting from the ChemACX database Version 5.5 
from CambridgeSoft Corp. (see chapter 4). For the sake of reasonable calculation 
time, the applied parameters were altered with respect to the sphere radius (6 Å in-
stead of 5 Å) and the number of lipophilic and polar interaction sites per protein atom 
(25 each instead of 35 before). Around 197000 compounds were screened in 5.5 
days with LUDI resulting in 1063 hits. The final selection of compounds for purchase, 
synthesis and enzyme testing included the following criteria: (a) a high LUDI score 
larger than 325, (b) commercial availability and (c) efficient synthetic feasibility. 
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A majority of the selected compounds were carboxylic acids or derivatives thereof 
(Table 3.1, compounds 2, 3, 7, 9, 11, 15 and 19) since the active site of hylB4755 is 
composed of several arginine residues. All other compounds also bear polar func-
tional groups which may favourably interact with these positively charged guanidino 
groups. For example, the proposed binding mode of compound 2 is shown in Figure 
3.3 as fit onto the calculated interactions sites. It shows favourable ionic interactions 
between its two carboxylic groups and the arginine residues Arg468 and Arg634 
bridging both ‘walls’ at the narrowest site of the HA binding cleft. Additionally, the 
proposed binding mode suggests a lipophilic interaction between the phenyl moiety 
of the ligand and Val579 constituting the bottom of the crevice (Val579 not shown in 
Figure 3.3 for the sake of clarity). Compound 17 from the LeadQuest® database was 
similarly docked** into the active site of hylB4755 bridging the binding site with its both 
acetyl groups. Additionally, the sulfur substituent points towards the Trp460 residue 
of the aromatic patch (see Figure 3.4, purple structure). Such a lipophilic interaction 
can be frequently observed in protein-ligand crystal structures.  
Based on the LUDI search, we assayed nineteen compounds for their abilities to in-
hibit the degradation of hyaluronic acid by the hyaluronan lyase from S. agalactiae 
strain 4755 (see Table 3.1).23 With respect to selectivity, the inhibitory activities of all 
compounds on the bovine testicular hyaluronidase (BTH) were determined, too (see 
chapter 5 and PhD thesis of Sunnhild Salmen23). 
Despite moderate LUDI scores, six (compounds 5, 6, 8, 10, 13 and 18) out of nine-
teen compounds induced no inhibition of the hyaluronate lyase up to the maximal test 
concentration. In contrast to these results, compound 1 of the adapted ChemACX 
database with the highest LUDI score moderately inhibited the activity of hylB4755 with 
IC50 values of 310 µM at catalytically optimal pH and 160 µM at physiological pH. 
                                            
**
 For the discussion of an alternative binding mode of compound 17 as suggested by additional LUDI 
calculations see section 3.2.3. 
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Table 3.1. Selected compounds with calculated LUDI scores, database source (A = Accelrys, C = 
ChemACX and LQ = LeadQuest® Database) and IC50 value determined on hylB4755 (n=3; SEM not 
larger than 1 %)23 
M
IC50
 
No. Structure 
LUDI Score 
Database  
pH 5.0 pH 7.4 
1 
O
O2N
O
 
687 
C  
310 160 
2 
CO2H
HO2C
 
579 
A 
 
3710 900 
3 
CO2H
CO2H
 
555 
A 
 
2680 
inactive 
(≤ 20 mM) 
4 
O
NO2O2N
 
505 
C  
2900 
inactive 
(≤ 5 mM) 
5 
N OCH3
 
452 
A 
 
inactive 
(≤ 20 mM) 
inactive 
(≤ 20 mM) 
6 
N
S
O
OCH3
 
441 
LQ  
inactive 
(≤ 5.25 mM) n.d. 
7 CO2HHO2C
 
436 
A 
 
2500 
inactive 
(≤ 20 mM) 
8 
N
CH3
O2N
CH3
H3C O
 
429 
LQ  
inactive 
(≤ 2.5 mM) n.d. 
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9 
N CO2H
OH
 
426 
A 
 
4470 
inactive 
(≤ 10 mM) 
10 
N
NN
O
 
407 
C  
inactive 
(≤ 0.1 mM) 
inactive 
(≤ 0.1 mM) 
11 N
CO2CH3
 
405 
A 
 
11000 5000 
12 N N
OCH3 O
CH3
 
392 
LQ  
38 %  
(20 mM) a 
83 %  
(15 mM) a 
13 
NC
NC O OC4H9
 
391 
LQ  
inactive 
(≤ 5 mM) n.d. 
14 
S
NO2
Cl
O
 
384 
LQ  
20 %  
(20 mM) a 
50 %  
(20 mM) a 
15 
O
CO2H
 
382 
A 
 
50 %  
(20 mM) a 
35 %  
(20 mM) a 
16 
O
O
N
 
364 
LQ  
610 
46 %  
(2 mM) a 
17 N
N
S
O
O
 
363 
LQ  
160 5 
18 N
O
 
357 
LQ  
inactive 
(≤ 20 mM) 
inactive 
(≤ 20 mM) 
19 
N
H
CO2H
 
328 
A 
 
3550 
44 %  
(20 mM)a 
a % inhibition at concentration given in parenthesis 
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Although the inhibitory activities of the compounds were determined at two different 
pH values, the predicted Ki value is only comparable with the measured IC50 value for 
pH 7.4 since the protonation states of the amino acid residues exposed to the active 
site were defined for a neutral pH. For compound 1, the predicted inhibition constant 
of ca. 1 µM and the measured IC50 value differ by a factor of around two orders of 
magnitude. Since other studies have shown predicted affinities by LUDI to be accu-
rate to about 1.3-1.5 lg units,20,24 this prediction is in accordance with the prediction 
accuracy of today’s scoring functions. 
The IC50 values for the aromatic dicarboxylic acids determined on the hyaluronate 
lyase at pH 5.0 were 3.7 mM (2), 2.7 mM (3) and 2.5 mM (5) and were lower than 
anticipated from the LUDI score. Presumably, the LUDI scoring function did not per-
form well due to inaccurately predicted hydrogen bonding contribution.25 Additionally, 
the LUDI scores just tend to overestimate binding of these compounds at a highly 
charged (pH-dependent) active site due to several ionic interactions (see discrete 
contributions to Böhm’s LUDI score, data not shown). For benzene-1,4-diacetic acid 
(2), an IC50 value of 0.9 mM was determined at physiological pH, whereas isophthalic 
acid (3) and terephthalic acid (7) showed no inhibition of the enzyme at neutral pH. It 
may be speculated about the factors accounting for the varying activity differences of 
the enzyme inhibitors at pH 5.0 and 7.4. In particular, the protonation state of the 
tested compounds depends on the pH value of the incubation mixture just like the 
protonation of amino acid residues inside the active site of the enzyme. 
Compounds 4 and 9 weakly inhibited the activity of hylB4755 at its catalytic pH opti-
mum with IC50 values of 2.9 mM (4) and 4.5 mM (9) whereas at physiological pH, no 
inhibition could be detected up to a concentration of 5 mM and 10 mM, respectively. 
Like in the other cases, the prediction of inhibitory activity based on the LUDI score 
differed significantly. Compounds 12, 14 and 15 only showed partial inhibition at the 
maximal test concentration for both pH values. At pH 5.0, compound 16 from the 
LeadQuest® database and indole-2-carboxylic acid (19) inhibited hylB4755 with 
IC50 values of 0.6 mM and 3.6 mM, respectively, but did not approach 50 % inhibition 
at physiological pH. Inspired by the inhibitory effect of compound 19, substitution 
patterns at the indole scaffold were explored leading to potent indole-based hyaluro-
nate lyase inhibitors in the micromolar range.23 An enzyme-inhibitor complex of 
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hylSpn with one of these potent inhibitors could be elucidated by means of X-ray 
crystallography.23 
Surprisingly, despite a predicted inhibition concentration of only around 1 mM, 1,3-
diacetylbenzimidazole-2-thione (17) potently inhibited the activity of hylB4755 with 
IC50 values of 5 µM at physiological pH and 160 µM at pH 5.0. Since for further modi-
fications and optimisation of the lead 1,3-diacetylbenzimidazole-2-thione (17) a de-
termination of the binding mode by analysing an enzyme-inhibitor complex would be 
beneficial, soaking experiments†† were accomplished. Probably due to instability 
against moisture and poor solubility, no X-ray structure of hylSpn complexed with 
compound 17 could be determined.27 Nonetheless, prompted by its promising inhibi-
tory activity, structural modifications of the mother substance are the subject of on-
going studies. 
3.2.3 Dependence of results on applied LUDI parameters – Comparison 
with Consensus Scoring methods and FlexX docking 
Since any virtual screening method has to face docking and scoring as two critical 
issues, the calculated LUDI results were firstly analysed for their dependence on the 
applied docking parameters. For developing a more efficient selection strategy, all 
nineteen compounds were investigated.  
In a first step, the calculated LUDI scores of selected compounds from the Lead-
Quest® database run were compared with the results of the combined database run 
with respect to the sphere radius and the flexibility of docked ligands. Additionally, 
the observed differences were related to the rms deviation of the docked poses‡‡ in 
each LUDI run. Results for five selected compounds are presented in Table 3.2.  
Compounds 2 and 3 from the Accelrys database were only included in searches us-
ing a sphere radius of 8 Å. Their calculated scores were compared with respect to 
rotating bonds present or not (irot = 1 or 0). For compound 2, LUDI suggested a 
rather similar spatial position in both calculations, but the predicted inhibition con-
stants differed by a factor of 35 (60 M and 1.6 M for the first and the second cal-
culation, respectively). This may result from a probably high overestimation of ionic 
                                            
††
 In cooperation, soaking experiments for 1,3-diacetylbenzimidazole-2-thione (17) with hylSpn were 
accomplished by M. J. Jedrzejas, Children’s Hospital Oakland Research Institute, Oakland, USA. 
‡‡
 target-bound conformation and orientation of each screened ligand 
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interactions (six instead of four) between the molecule’s carboxylic moieties and the 
amino acid residues Arg468 and Arg634 of the enzyme (data not shown, see Figure 
3.3). Additionally, these ionic interactions as well as hydrogen bonds are direc-
tional,28 i.e. they significantly depend on the spatial arrangement of the ligand and the 
interacting groups of the protein. By contrast, the results for compound 3 did not vary 
upon alteration of flexibility parameters. But also in this case, the LUDI score seems 
to be largely overestimated because of ionic interactions. 
This problem might be tackled by changing the protonation states of the carboxylic 
functions on both molecules. During the automated generation of the GENFRA data-
bases, the protonation states of the processed compounds may be defined by ap-
plying a special parameter. This parameter could not be altered due to an error in the 
LUDI programme supplied by Accelrys. Unfortunalely, despite of intensive efforts to 
solve this issue, the Accelrys hot line could not provide a fix for this crucial error. Al-
ternatively, both compounds were treated as uncharged carboxylic acids after manu-
ally altering the protonation states, but then they were not retrieved by LUDI (data not 
shown). 
Although compound 6 was docked in an identical position by LUDI (rmsd = 0.00 Å), 
the calculated LUDI scores were slightly dependent on the sphere radius, but not on 
the allowed flexibility of the ligand. Probably, a larger sphere with more and/or addi-
tional, differently typed interaction sites (in this case hydrogen donor sites) led to this 
observed change because the LUDI scoring function is cumulative with respect to the 
free energy contribution from hydrogen bonds, ionic, and lipophilic interactions.28 The 
LUDI scores of compound 12 vary in similar manner as in the case of compound 6. 
The slight difference of the docking positions (rms deviation of 0.89 Å) might reflect 
the dependence of the scores on the absolute position of the interacting functional 
groups of the ligand and the protein. For compound 17, a significantly different effect 
can be observed. Despite a fairly similar LUDI score for all four settings, the respec-
tive docking pose is strikingly different with a rms distance of 4.65 Å as depicted in 
Figure 3.4. This result underlines that alternative poses of the ligand might lead to 
similar LUDI scores and, thus, similar predicted inhibition constants. An identification 
of the native binding mode, either manual or by means of the docking programme, is 
therefore a basic requisite for the reliable prediction of binding affinities.11  
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Several methods were described in the literature for slightly differing scenarios like 1) 
structure-based inhibitor design,29,30 2) virtual screening by pharmacophore filters,24 
and 3) validation of scoring functions.31,32 In the first scenario, Grädler et al. cali-
brated the LUDI score starting from a protein-ligand complex of a substrate-like in-
hibitor with known Ki value by adjusting the LUDI parameters so that the calculated 
pose resembles the detected binding mode of the co-crystallised ligand and that the 
predicted score corresponds to the measured Ki value. Following this approach, the 
X-ray structure of hylSpn complexed with L-ascorbic acid4 could suit as reference. 
After superposition of the hylSpn-vitamin C structure with the hylB4755 model, vita-
min C was merged into the model, and a very low LUDI score of 64 corresponding to 
a predicted Ki value of 230 mM was calculated (For comparison, the measured 
IC50 value of L-ascorbic acid on hylB4755 is 5 mM, see chapter 6.). Therefore, vitamin 
C could not serve as a reference since its LUDI score falls below the threshold of 300 
for acceptable values and, moreover, since it could not be retrieved in several LUDI 
calculation attempts.  
Table 3.2. Overview of the calculated LUDI Score in dependence of the applied parameter and 
of the resulted docking accuracy 
Compound  
No. LUDI Score
a
  rmsd 
 
r = 5 Å 
irot = 0 
r = 5 Å 
irot = 1 
r = 8 Å 
irot = 0 
r = 8 Å 
irot = 1  in Å 
2 — — 422 579  1.44b 
3 —- — 555 555  0.00b 
6 400 400 441 441  0.00c 
12 421 421 392 392  0.89c 
17 343 343 363 363  4.65c 
aCalculated LUDI score with indicated parameters for sphere radius r and rotatable bonds on or off (irot = 1 or 0)  
b
rms deviation between the pose positions calculated with parameters r = 8 Å, rotatable bonds off (irot = 0) and 
parameters r = 8 Å, rotatable bonds on (irot = 1) 
c
rms deviation between the pose positions calculated with parameters r = 5 Å, rotatable bonds off (irot = 0) and 
parameters r = 8 Å, rotatable bonds on (irot = 1)   
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Figure 3.4. Two putative binding modes of compound 17 dependent on the LUDI sphere radius (5 Å, 
purple, 8 Å, green) encompassing the active site of the hylB4755 model. Hydrogen bonds (yellow) be-
tween both acetyl substitutents of the molecule and Arg409 and Arg634 are depicted in dashed style. 
A pilot project for virtual screening of human carboanhydrase II inhibitors published 
by Grüneberg et al.24,33 represents the second scenario. In their work, a hierarchical 
filtering strategy was applied using a 2D query for essential functional groups, sub-
sequently a 3D pharmacophore query and finally a similarity scoring with FlexS34 
based on known potent inhibitors resulting in around 3300 of 90000 compounds at 
the beginning. The 100 best scoring molecules were then flexibly docked with 
FlexX35 and ranked by FlexX score and DrugScore.36  
The third scenario was described by Stahl et al. who presented a detailed analysis of 
scoring functions for virtual screening using the programme FlexX as docking en-
gine.32 A well-chosen combination of two tested scoring functions led to a new, ro-
bust scoring scheme called ScreenScore, which is implemented in the latest versions 
of FlexX. The results obtained with ScreenScore were compared with those from the 
combination of other scoring functions, a method called ‘consensus scoring’.37 It was 
suggested that consensus scoring offered more robust results than individual scoring 
functions.38  
Structure-based design of hyaluronate lyase inhibitors 
 
41 
In the present work, we attempted to combine approaches from the second and the 
third scenario in order to obtain a more reliable selection of compounds. In the first 
step, a consensus scoring of all hits from the calculation with the combined data-
bases was envisaged. To date, several consensus scoring approaches like the 
CScore modul implemented in SYBYL39 and X-Score40 have been described in litera-
ture. Since X-Score was readily available from the authors, all hits from the combined 
databases run were re-scored using standard parameters. The hylB4755 model and 
the poses of all hits were taken as calculated by LUDI in the combined database run. 
The results of this re-scoring approach with X-Score are summarised in Table 3.3.  
The comparison of the ranking order of both scoring functions revealed that the se-
lected compounds were all resorted by the X-Score scoring function. But, in general, 
the predicted Ki and Kd values of most investigated compounds are rather similar, 
e.g. for compound 2 with Ki = 1.6 µM as LUDI and Kd = 4.4 µM as X-Score prediction. 
Only compounds 11, 18 and 19 differ in their predicted Ki and Kd values, respectively, 
by more than one order of magnitude. Such discrepancies are certainly due to the 
different ‘basis sets’ of the scoring functions. On the one hand, no standardised data 
set of protein-ligand complexes exists for calibration and, on the other hand, the 
number and type of appropriate biological systems is rather limited.11 Nevertheless, 
Table 3.3 shows that the selection of compounds by their X-Score is as effective as 
using the LUDI score with respect to picking of potentially active inhibitors. 
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In general, active compounds are more reliably predicted if a docking engine like 
LUDI reproduces crystallographically observed (native-like) binding modes within a 
certain accuracy reflected by a rms deviation below 2.0 Å.24,32,41 
Recently, in order to cover the entire conformational space of the candidate mole-
cules as well as possible and then to retrieve their native-like binding geometries, 
flexible docking of the selected compound set followed by – at best – a consensus 
scoring scheme was proposed.24,41,42 In our study, we tried to adapt a similar strategy 
to investigate whether it would facilitate the selection of compounds.  
Table 3.3. Comparison of calculated LUDI score and X-Score for selection of proposed 
compounds 
Compound No. LUDI scorea  X-Scoreb  Inhibitory activityc 
 rank score  rank score   
2 1 579  2 5.36  + 
3 2 555  15 5.10  + 
5 6 452  32 4.78  – 
7 10 436  127 3.96  + 
9 17 426  141 3.78  + 
11 32 403  1 5.41  + 
12 46 392  146 3.65  + 
13 49 391  90 4.30  – 
14 57 384  75 4.43  + 
16 79 364  53 4.60  + 
17 80 363  116 4.04  + 
18 89 357  32 4.78  – 
19 131 328  15 5.10  + 
a 10010
score
iK
−
=  
b score
dK
−
= 10  
c
 ligand with inhibitory activity on hylB4755: +; ligand without inhibitory activity on hylB4755: – 
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Therefore, all proposed hits of the combined database run were subjected to an 
automated flexible docking procedure using FlexX with standard parameters. The 
results of the FlexX calculations are summarised in Table 3.4. For comparison, the 
poses calculated by LUDI were taken as reference since LUDI is supposed to be 
able to predict reliable binding modes.30,43 A rms deviation smaller than 2 Å between 
FlexX and LUDI poses was taken as a criterion for the prediction of a LUDI-like 
binding mode.  
Table 3.4. Overview of FlexX results with respect to docking score and docking accuracy 
compared to poses calculated by LUDI 
Compound 
No. 
LUDI-like posea  FlexX best poseb  Inhibitory activityc 
 score  rmsd/Å  score rmsd/Å   
5 -22.59 0.97  -26.57 2.05  – 
12 -14.84 3.78  -15.88 4.88  – 
19 -12.87 0.41  -14.20 4.93  + 
7 -12.59 1.34  -22.72 5.34  + 
2 -12.06 1.61  -18.70 5.89  + 
11 -12.02 0.91  -14.20 4.74  + 
13 -11.77 5.32  -17.46 6.82  – 
3 -11.45 1.53  -13.56 3.09  + 
17 -10.08 0.95  -16.83 5.31  + 
16 -9.37 1.57  -18.52 8.42  + 
9 -8.72 1.14  -15.41 7.89  + 
14 -7.68 1.13  -19.43 5.62  – 
18 -3.56 1.85  -10.68 14.46  – 
a FlexX-Score of  the FlexX pose with the lowest rmsd compared to the LUDI pose from the 
combined database run 
bFlexX pose with the best FlexX-Score among all poses, rmsd compared to the LUDI pose 
from the combined database run 
c
 ligand with inhibitory activity on hylB4755: +; ligand without inhibitory activity on hylB4755: – 
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For each of the investigated hits, the pose with the best FlexX score and the LUDI 
pose are very different (column FlexX best pose). There is no correlation between 
the FlexX scores and inhibitory activity so that a compound selection uniquely based 
upon this score is not more efficient than a selection based on any other scoring 
function. However, when the most LUDI-like FlexX poses are considered, the predic-
tion is improved. Apart from two inactive compounds (12 and 13) where FlexX did not 
find a LUDI-like pose and one outlier (compound 5) with no inhibitory activity but high 
FlexX score, this double-docking-double-scoring procedure may be able to privilege 
active ligands (e.g. compounds 7 and 19 vs. compounds 14 and 18) and should 
therefore be applied for the selection of new compounds in future work. 
3.3 Summary and future perspectives 
Starting from two crystal structures of streptococcal hyaluronate lyases hylSpn and 
hylB3502, a homology model of S. agalactiae strain 4755 hyaluronate lyase hylB4755 
was constructed. This homology model was applied to structure-based ligand design 
with the de novo design programme LUDI. The three databases LeadQuest® Vol. 
1&2, Accelrys and an adapted ChemACX database containing 228000 compounds 
were screened resulting in 1275 hits. Based on high LUDI scores, synthetic feasibility 
and commercial availability, nineteen of these putative ligands were selected, subse-
quently purchased or synthesised and investigated for their abilities to inhibit the deg-
radation of hyaluronic acid by the hyaluronan lyase from S. agalactiae strain 4755. 
Thirteen compounds were active on hylB4755 in the milli- and submillimolar range, six 
did not inhibit the enzyme up to the highest concentration tested. 1,3-Diacetylbenz-
imidazole-2-thione (17) with IC50 values of 5 µM and 160 µM at physiological pH and 
optimum pH, respectively, is one of the most potent inhibitors of hyaluronate lyases 
known to date. Prompted by this promising result, structural modifications of the 
compound 17 are the subject of ongoing studies. 
Based on the results of the investigated compounds, theoretical investigations were 
carried out. Using the re-scoring scheme with X-Score and subsequently the auto-
mated flexible docking programme FlexX, a double-docking-double-scoring strategy 
was derived which seems to improve the selection and lead optimisation of hyaluro-
nate lyase inhibitors. 
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Besides the programmes DrugScore36 and GRID,44 LUDI is capable to extract H-do-
nor, H-acceptor and lipophilic interaction sites which can be converted into a complex 
pharmacophore refined by the analysis of known hyaluronate lyase-inhibitor com-
plexes (see chapter 7 and reference 23). Subsequently, based on this pharma-
cophore, databases like ChemACX could be screened using INSIGHT or CATA-
LYST. Such a strategy was shown to be successful in several drug design scenar-
ios33,42 and could be complemented by the FlexX-Pharm programme, a flexible dock-
ing procedure using pharmacophore-type constraints.45 
3.4 Experimental section 
3.4.1 Theoretical methods 
3.4.1.1 HylB4755 model construction 
The coordinates for the bacterial hyaluronan lyase from S. pneumoniae (pdb code: 
1c82)46 and the lyase from S. agalactiae strain 3502 (pdb code: 1f1s)4 were obtained 
prior to publication from M. J. Jedrzejas, Children’s Hospital Oakland Research In-
stitute, Oakland, USA. The sequence identity between hylSpn and hylB4755 is 53 %, 
between hylB4755 and hylB3502 even 98 %. For a homology modelling approach the 
crystal structure of hylSpn was used as template, since its conformation is supposed 
to be catalytically active whereas the crystallised state of hylB3502 is not optimal for 
catalysis.14 Compared to hylSpn, the α-domain of hylB3502 is rotated by a small angle 
around the linker II with respect to the β-II-domain.14 As a result, the hylB3502 struc-
ture is more open than the hylSpn conformation. Consequently, corresponding sub-
domains of hylSpn and hylB3502 were superimposed using SYBYL 6.8 (Tripos Inc., St. 
Louis, USA) on an Indigo² workstation running IRIX 6.5. The superposition of all α-
helices of the corresponding α-domains (Asn251-Leu610 and Thr173-Leu530 for 
hylB3502 and hylSpn, respectively) resulted in a rms distance of 0.8 Å, whereas the 
corresponding β-II-domains (Asn623-Asn972 for hylB3502 and Tyr543-Asn874 for 
hylB3502 and hylSpn, respectively) are even more similar with a rms distance of 
0.65 Å. A full model of hylB4755 was constructed by starting from the hylB3502 α- and 
β-II-domains with lowest rms distance to hylSpn, inserting joining loops from hylB3502, 
and mutating eight amino acids to achieve the hylB4755 amino acid sequence. The 
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resulting model with hydrogens added was energetically minimised using the Am-
ber4.1 force field. 
The LeadQuest® databases Vol. 1&2 (May 1998, 23341 molecules21) and the 
adapted ChemACX database (see chapter 4) were converted into 3D using the 
CONVERTER module from Insight 2000 (Accelrys Inc., San Diego, USA). All-trans 
conformations of chains and chair conformations of 6-membered rings consisting of 
only sp3 atoms were adjusted to allow for energy minimum conformations of the re-
sulting 3D structures. For each molecule of the original 2D databases two stereo-
isomeres (if possible) were generated, yielding 28717 structures for the LeadQuest® 
databases and 196908 structures for the ChemACX database. The resulting data-
bases were prepared for use with the LUDI programme (Accelrys Inc.) by means of 
the LUDI module GENFRA 57,48 constructing a structure and a target database with 
types of each target site (e.g. H-acceptor or H-donor atom) in the fragments. 
3.4.1.2 LUDI calculations with the hylB4755 model 
A LUDI approach was set up with a sphere of 5 Å radius within the active site of 
hylB4755. The centre of this sphere was determined as the arithmetic mean of five 
amino acid residues belonging to the active site (Arg409, Trp460, Tyr576, Val579 
and Arg634). The values of the most important LUDI parameters for the design of 
hylB4755 ligands were as follows: the maximal rms distance of the fit between the 
fragment and the interaction sites was 0.45 Å, the number of lipophilic and polar in-
teraction sites per protein atom was set to 35 and the minimal contact surface be-
tween ligand and protein was set to 30 %. The retrieved candidate molecules were 
ranked with respect to their expected binding affinity using the empirical scoring 
function developed by Böhm43 with a minimal scoring value of 300 (predicted Ki value 
of 1 mM). All other parameters were set to default values. Performing a LUDI run with 
the constructed LeadQuest® database resulted in 122 hits. To enable a larger sphere 
(r = 8 Å) and to consider rotatable bonds in reasonable CPU time, these hits were 
combined with 1020 compounds from the Accelrys database supplied with the LUDI 
module. Recalculation with this combined hit database led to the extraction of 212 
new hits. Sixteen of these hits were selected for testing hyaluronidase inhibition ac-
cording to high LUDI scores, availability and efficient synthetic feasibility. Additionally, 
for the sake of shorter calculation time, the adapted ChemACX database (see chap-
ter 4) was filtered by LUDI using more restricted conditions (sphere radius of 6 Å in-
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stead of 5 Å and a density of lipophilic and polar interaction sites of 25 instead of 35 
sites per protein atom). Three out of 1063 compounds were selected for testing hya-
luronidase inhibition. 
3.4.1.3 Re-scoring of LUDI poses with X-Score 
For re-scoring using the X-Score programme,40 all LUDI poses from the combined 
database run were converted into a multi-mol2 file by the SYBYL module DBTRANS-
LATE. Polar hydrogen atoms were added to the hylB4755 model, and it was saved in 
pdb format. Subsequently, the X-Score run was set up for all hits and the results 
were analysed in comparison to the calculated LUDI scores.  
3.4.1.4 Re-docking of LUDI poses with FlexX Version 1.11 
All LUDI poses of the combined database run were converted into a multi-mol2 file 
using the SYBYL module DBTRANSLATE and splitted into single mol2 files for use 
with FlexX Version 1.11.35,49,50 Protonation states of the molecules were adjusted to 
generate the structure predominating at neutral pH. The binding site was manually 
defined by means of the interactive modelling programme SYBYL 6.8. For flexible 
docking, the binding pocket from the LUDI run with a sphere of 5 Å was selected. 
The hit set was docked into the target active site using the default FlexX parameter 
settings contained in the FlexX distribution. For each entity of the hit set, the LUDI 
pose was taken as reference for further analysis. Final scores were calculated for all 
FlexX poses (up to 800) per compound.  
3.4.2 Test compounds 
The test compounds were either purchased from Acros Organics BVBA (Belgium), 
Lancaster Synthesis GmbH (Germany), Maybridge Chemical Company (United 
Kingdom), Sigma-Aldrich Chemie GmbH (Germany) and Tripos Receptor Research 
Ltd. (United Kingdom) or synthesised according to literature procedures by Sunnhild 
Salmen.23  
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3.4.3 Pharmacological methods 
The inhibitory effect of the compounds on the activity hyaluronidases were deter-
mined23 by the method of Reissig51 based on the Morgan-Elson reaction and by a 
turbidimetric assay according to the description of Di Ferrante.52 
3.5 References 
(1) Glycoforum http://www.glycoforum.gr.jp/, 2003. 
(2) Hynes, W.; Walton, S. Hyaluronidases of gram-positive bacteria. FEMS Microbiol Lett 2000, 
183, 201-207. 
(3) Akhtar, M. S.; Bhakuni, V. Streptococcus pneumoniae hyaluronate lyase contains two non-
cooperative independent folding/unfolding structural domains: characterization of functional do-
main and inhibitors of enzyme. J Biol Chem 2003, 278, 25509-25516. 
(4) Li, S.; Taylor, K. B.; Kelly, S. J.; Jedrzejas, M. J. Vitamin C inhibits the enzymatic activity of 
Streptococcus pneumoniae hyaluronate lyase. J Biol Chem 2001, 276, 15125-15130. 
(5) Moon, J. B.; Howe, W. J. Computer design of bioactive molecules: a method for receptor-based 
de novo ligand design. Proteins 1991, 11, 314-328. 
(6) Nishibata, Y.; Itai, A. Automatic creation of drug candidate structures based on receptor struc-
ture. Starting point for artificial lead generation. Tetrahedron 1991, 47, 8985-8990. 
(7) Böhm, H. J. The computer program LUDI: a new method for the de novo design of enzyme 
inhibitors. J Comput Aided Mol Des 1992, 6, 61-78. 
(8) Böhm, H. J. LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J 
Comput Aided Mol Des 1992, 6, 593-606. 
(9) Schneider, G.; Böhm, H. J. Virtual screening and fast automated docking methods. Drug Discov 
Today 2002, 7, 64-70. 
(10) Böhm, H. J. Current computational tools for de novo ligand design. Curr Opin Biotechnol 1996, 
7, 433-436. 
(11) Gohlke, H.; Klebe, G. Approaches to the description and prediction of the binding affinity of 
small-molecule ligands to macromolecular receptors. Angew Chem Int Ed Engl 2002, 41, 2644-
2676. 
(12) Klebe, G.; Grädler, U.; Grüneberg, S.; Krämer, O.; Gohlke, H. Understanding receptor-ligand 
interactions as a prerequisite for virtual screening. Virtual Screening for Bioactive Molecules; 
Wiley-VCH: Weinheim, 2000; pp 207-227. 
(13) Li, S.; Kelly, S.; Lamani, E.; Ferraroni, M.; Jedrzejas, M. Structural basis of hyaluronan degrada-
tion by Streptococcus pneumoniae hyaluronate lyase. EMBO J 2000, 19, 1228-1240. 
(14) Li, S.; Jedrzejas, M. J. Hyaluronan binding and degradation by Streptococcus agalactiae 
hyaluronate lyase. J Biol Chem 2001, 276, 41407-41416. 
Structure-based design of hyaluronate lyase inhibitors 
 
49 
(15) Mello, L. V.; De Groot, B. L.; Li, S.; Jedrzejas, M. J. Structure and flexibility of Streptococcus 
agalactiae hyaluronate lyase complex with its substrate. Insights into the mechanism of proces-
sive degradation of hyaluronan. J Biol Chem 2002, 277, 36678-36688. 
(16) Sanchez, R.; Sali, A. Comparative protein structure modeling. Introduction and practical exam-
ples with modeller. Methods Mol Biol 2000, 143, 97-129. 
(17) Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: improving the sensitivity of 
progressive multiple sequence alignment through sequence weighting, position-specific gap 
penalties and weight matrix choice. Nucleic Acids Res 1994, 22, 4673-4680. 
(18) Higgins, D. G.; Sharp, P. M. CLUSTAL: a package for performing multiple sequence alignment 
on a microcomputer. Gene 1988, 73, 237-244. 
(19) Jedrzejas, M. J.; Mello, L. V.; De Groot, B. L.; Li, S. Mechanism of hyaluronan degradation by 
Streptococcus pneumoniae hyaluronate lyase: Structures of complexes with the substrate. J 
Biol Chem 2002. 
(20) Böhm, H. J. Prediction of binding constants of protein ligands: a fast method for the prioritization 
of hits obtained from de novo design or 3D database search programs. J Comput Aided Mol 
Des 1998, 12, 309-323. 
(21) LeadQuest Chemical Compounds Libraries; Vol. 1-2 ed.; Tripos, Inc.: St. Louis, USA, 2000. 
(22) Accelrys, Inc. CONVERTER in Insight2000. 
(23) Salmen, S. Inhibitors of bacterial and mammalian hyaluronidases: synthesis and structure-activ-
ity relationships; University of Regensburg: Regensburg, 2003. 
(24) Grüneberg, S.; Wendt, B.; Klebe, G. Subnanomolar Inhibitors from Computer Screening: A 
Model Study Using Human Carbonic Anhydrase II. Angew Chem Int Ed Engl 2001, 40, 389-393. 
(25) Ajay; Murcko, M. A. Computational methods to predict binding free energy in ligand-receptor 
complexes. J Med Chem 1995, 38, 4953-4967. 
(26) Kelly, S. J.; Taylor, K. B.; Li, S.; Jedrzejas, M. J. Kinetic properties of Streptococcus pneumo-
niae hyaluronate lyase. Glycobiology 2001, 11, 297-304. 
(27) Jedrzejas, M. personal communication, 2003. 
(28) Böhm, H. J. The development of a simple empirical scoring function to estimate the binding 
constant for a protein-ligand complex of known three- dimensional structure. J Comput Aided 
Mol Des 1994, 8, 243-256. 
(29) Grädler, U. De Novo-Design und Strukturbestimmung von Inhibitoren der tRNA-Guanin 
Transglykosylase aus Zymomonas mobilis als neues Target der Bakterienruhr. Institut für 
Pharmazeutische Chemie und Biochemie; Philipps-Universität Marburg: Marburg, 2000. 
(30) Grädler, U.; Gerber, H. D.; Goodenough-Lashua, D. M.; Garcia, G. A.; Ficner, R. et al. A new 
target for shigellosis: rational design and crystallographic studies of inhibitors of tRNA-guanine 
transglycosylase. J Mol Biol 2001, 306, 455-467. 
(31) Schulz-Gasch, T.; Stahl, M. Binding site characteristics in structure-based virtual screening: 
evaluation of current docking tools. J Mol Model (Online) 2003, 9, 47-57. 
(32) Stahl, M.; Rarey, M. Detailed analysis of scoring functions for virtual screening. J Med Chem 
2001, 44, 1035-1042. 
Structure-based design of hyaluronate lyase inhibitors 
 
50 
(33) Grüneberg, S.; Stubbs, M. T.; Klebe, G. Successful virtual screening for novel inhibitors of hu-
man carbonic anhydrase: strategy and experimental confirmation. J Med Chem 2002, 45, 3588-
3602. 
(34) Lemmen, C.; Lengauer, T.; Klebe, G. FLEXS: a method for fast flexible ligand superposition. J 
Med Chem 1998, 41, 4502-4520. 
(35) Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incre-
mental construction algorithm. J Mol Biol 1996, 261, 470-489. 
(36) Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand 
interactions. J Mol Biol 2000, 295, 337-356. 
(37) Charifson, P. S.; Corkery, J. J.; Murcko, M. A.; Walters, W. P. Consensus scoring: A method for 
obtaining improved hit rates from docking databases of three-dimensional structures into pro-
teins. J Med Chem 1999, 42, 5100-5109. 
(38) Stahl, M.; Böhm, H. J. Development of filter functions for protein-ligand docking. J Mol Graph 
Model 1998, 16, 121-132. 
(39) Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Consensus scoring for 
ligand/protein interactions. J Mol Graph Model 2002, 20, 281-295. 
(40) Wang, R.; Lai, L.; Wang, S. Further development and validation of empirical scoring functions 
for structure-based binding affinity prediction. J Comput Aided Mol Des 2002, 16, 11-26. 
(41) Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular dock-
ing. J Med Chem 2003, 46, 2287-2303. 
(42) Brenk, R.; Naerum, L.; Grädler, U.; Gerber, H. D.; Garcia, G. A. et al. Virtual screening for 
submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding 
mode detected by crystal structure analysis. J Med Chem 2003, 46, 1133-1143. 
(43) Böhm, H. J. On the use of LUDI to search the Fine Chemicals Directory for ligands of proteins of 
known three-dimensional structure. J Comput Aided Mol Des 1994, 8, 623-632. 
(44) Goodford, P. J. A computational procedure for determining energetically favorable binding sites 
on biologically important macromolecules. J Med Chem 1985, 28, 849-857. 
(45) Hindle, S. A.; Rarey, M.; Buning, C.; Lengauer, T. Flexible docking under pharmacophore type 
constraints. J Comput Aided Mol Des 2002, 16, 129-149. 
(46) Ponnuraj, K.; Jedrzejas, M. Mechanism of Hyaluronan Binding and Degradation: Structure of 
Streptococcus pneumoniae Haluronate Lyase in Complex with Hyaluronic Acid Disaccharide at 
1.7 A Resolution. J Mol Biol 2000, 299, 885-895. 
(47) Tripos LEADQUEST Chemical Compounds Libraries Vol. 1 & 2. http://www.tripos.com 1998. 
(48) Böhm, H. J. A novel computational tool for automated structure-based drug design. J Mol 
Recognit 1993, 6, 131-137. 
(49) Rarey, M.; Kramer, B.; Lengauer, T. Docking of hydrophobic ligands with interaction-based 
matching algorithms. Bioinformatics 1999, 15, 243-250. 
(50) Rarey, M.; Kramer, B.; Lengauer, T. Multiple automatic base selection: protein-ligand docking 
based on incremental construction without manual intervention. J Comput Aided Mol Des 1997, 
11, 369-384. 
(51) Reissig, J.; Strominger, J.; Leloir, L. A modified colorimetric method for the estimation of N-Ace-
tylamino sugars. J Biol Chem 1955, 217, 959-966. 
Structure-based design of hyaluronate lyase inhibitors 
 
51 
(52) Di Ferrante, N. Turbidimetric measurement of acid mucopolysaccharides and hyaluronidase 
activity. J Biol Chem 1956, 220, 303-306. 
Structure-based design of hyaluronate lyase inhibitors 
 
 
 
52
Generation and property analysis of virtual screening databases  
 
 53 
Chapter 4 Generation and property analysis of vir-
tual screening databases 
4.1 Introduction 
Over decades, strategies for drug discovery have not changed much. Natural prod-
ucts isolated from plants and microorganisms or leads resulting from a biochemical 
concept or just from serendipitous findings were structurally modified to obtain ana-
logues with improved activity, selectivity, bioavailability and/or less toxicity.1 Regard-
ing the physicochemical properties of these leads, compounds with poor solubility 
and/or chemical instability in a congeneric series were discarded and most often the 
starting lead was in a range of physicochemical properties consistent with the histori-
cal record of discovering orally active compounds.2  
In recent years, the sources of drug leads in the pharmaceutical industry have 
changed significantly. Apart from experimental high-throughput screening (HTS) of 
large compound libraries, increasingly provided by combinatorial chemistry, compu-
tational methods for virtual screening and de novo design have emerged due to the 
immense enhancement of computational power. Compound libraries with 102 to 106 
structures contain virtual and/or preferentially existing compounds that can either be 
synthesised in-house or in principle purchased from external sources. The Available 
Chemical Directory (ACD),3 the LeadQuest® libraries,4 and the ChemStar Library5 
etc. have recently been used for de novo design and virtual screening approaches.6-9 
Furthermore, diverse and focused library design (for lead optimisation) were applied 
to improve hit rates from experimental HTS and virtual screening.10  
Due to low ‘drugability’ with respect to poor ADMET properties (absorption, distribu-
tion, metabolism, excretion, toxicity), not all compounds which can be synthesised or 
are in present compound libraries are worthy of screening on the targets of interest. 
Thus, pre-filtering of databases to remove compounds with non drug-like characteris-
tics is frequently accomplished. It has been found that physicochemical and chemical 
parameters of most drugs fall into certain ranges indicating favourable ADMET be-
haviour. Lipinski’s empirical ‘rules of 5’ use simple, fast calculable (physico)chemical 
properties like the molecular weight range, log P range, numbers of H-bond donors, 
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and numbers of H-bond acceptors to predict the drug-likeness.2 Thus, filtering of 
databases with respect to Lipinski’s rules should lead to collections of ‘drugable’ 
compounds. 
In this chapter, based on ‘Lipinski-like’ filters, we describe the compilation of a library 
suitable for virtual screening starting from the commercially available ChemACX11 
compound collection. Furthermore, the resulting ChemACXF database, the Lead-
Quest® libraries Vol. 1&2 and Vol. 1-3 as well as the Accelrys12 database, all used for 
de novo ligand design approaches (see chapters 3 and 5), were analysed according 
to a description of property distribution of drug-related databases by Oprea.13 
Additionally, the property analysis for all de novo design hits from the LeadQuest® 
and ChemACXF databases (chapter 3) in comparison to the distribution of the origi-
nal databases should give insights into the capability of the programme LUDI to ex-
tract molecules meeting the LUDI-derived pharmacophore features with similar 
(physico)chemical properties. 
4.2 Results and discussion 
4.2.1 Analysis of databases suitable for virtual screening 
In principle, molecular databases which are virtually screened for structure-based 
ligand design should contain commercially available compounds or compounds 
which are readily synthetically feasible. Additionally, hits from these computational 
approaches should have physicochemical properties that allow favourable pharma-
cokinetics as postulated by Lipinski’s ‘rules of 5’.2 Therefore, we compiled a virtual 
screening database starting from the ChemACX collection of commercially available 
compounds. All entities with a molecular weight between 100 g/mol and 500 g/mol 
were retained. Additionally, compounds with reactive functional groups were dis-
carded (Figure 4.6). The resulting ChemACXF database (196908 molecules), along 
with the LeadQuest® libraries Vol. 1&2 (28717 molecules) and Vol. 1-3 (87095 mole-
cules), and the Accelrys database (1063 molecules) were used for virtual screening 
purposes (see chapter 3). LeadQuest® is a library of drug-like, synthetically feasible 
screening compounds, which provides an ideal source for the discovery of novel 
leads in terms of both structural diversity and chemical purity.6 The aforementioned 
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databases were analysed with respect to ‘Lipinski-like’ rules2,13 to investigate the 
drug-likeness of screened compounds. 
4.2.1.1 Molecular weight 
The molecular weight (MW) distribution of all databases is shown in Figure 4.1A. The 
LeadQuest® and the ChemACXF databases follow a Gaussian distribution, whereas 
about 60 % of all compounds from the Accelrys database are small molecules with a 
MW below 150 g/mol, and nearly 97 % below 250 g/mol. In contrast to ChemACXF 
with a median§§ around 200 g/mol and about 92 % of the molecular weights below 
350 g/mol, the medians of the LeadQuest® databases show a tendency towards in-
creased MW of ca. 320 g/mol for database volumes 1&2 and ca. 400 g/mol for vol-
umes 1-3. In general, the LeadQuest® libraries Vol.1-3 contain larger molecules than 
libraries Vol. 1&2 and thus, upgrades of LeadQuest® include more compounds with 
higher molecular weight.  
4.2.1.2 Partition coefficient 
The distribution of the calculated partition coefficient XLOGP14 of all database entries 
is shown in Figure 4.1B. All databases follow a Gaussian-like distribution which is 
relatively narrow in the case of the Accelrys and the LeadQuest® databases and less 
steep for LeadQuest® Vol. 1&2 compared to Vol. 1-3 and Accelrys. The ChemACXF 
database has a broad and shallow distribution. It is notable that its entities span the 
whole spectrum from very polar compounds (XLOGP = -4.5) to very hydrophobic 
compounds (XLOGP = 9.5). In contrast to the Accelrys and ChemACXF databases 
with medians around 1.2 and 1.5, respectively, the LeadQuest® databases have sig-
nificantly larger medians at XLOGP values of around 3.0-3.5. Comparing both Lead-
Quest® databases, Vol. 1-3 shows a symmetric, well-balanced XLOGP distribution, 
whereas Vol. 1&2 is more asymmetric due to the accumulation of very hydrophobic 
compounds. The analysis of a collection of pharmaceutical compounds from Com-
prehensive Medicinal Chemistry (CMC)13 with measured log P values also displays a 
Gaussian distribution with a median around 1.8. In a comparative study of 15 log P 
calculation procedures, the XLOGP programme proved to be among the best per-
forming procedures with respect to acceptably predicted log P values and a correla-
tion coefficient r of 0.971 for experimental and calculated data.14 
                                            
§§
 A median is defined as the point where the sum of cumulative percentage values reaches 50 % of 
all database entries. 
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Table 4.1. Percentage values of compounds within distinct intervals of calculated partition coefficient 
for investigated databases 
Database Percentage of Compounds 
with -0.5 < XLOGP ≤ 4.5 
Percentage of Compounds 
with 0.5 < XLOGP ≤ 3.5 
LeadQuest® Vol. 1&2 60.5 % 49.1 % 
LeadQuest® Vol. 1-3 85.6 % 73.2 % 
Accelrys 84.7 % 58.2 % 
ChemACXF 71.0 % 47.9 % 
CMCa 79.0 % 61.0 % 
a
 Measured log P values only. Adapted from Oprea et al.13 
Comparing the percentage of compounds with XLOGP values between 0.5 and 3.5 
(Table 4.1), the investigated databases fall into two classes: the LeadQuest® Vol. 
1&2 as well as the ChemACXF databases with about 50 % of compounds and the 
Accelrys as well as the LeadQuest® Vol. 1-3 databases with about 60 % and more 
compounds in this interval. The fraction of compounds with XLOGP values between 
0.5 and 3.5 of the latter databases is in good agreement with the analysis of the CMC 
and the NCE (New Chemical Entities) collections by Oprea13 reporting that data-
bases of pharmaceutically active compounds like NCE and CMC consist of more 
compounds in the 0 to 3 log P range than non-drug databases. 
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Figure 4.1. Distribution of A) molecular weight (MW) and B) XLOGP14 for LeadQuest® libraries Vol. 
1&2 and Vol. 1-3, Accelrys, and ChemACXF databases. 
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4.2.1.3 Number of hydrogen bond acceptors 
The distribution of the number of H-bond acceptors nacc is positively skewed in all 
databases (Figure 4.2A). Both LeadQuest® databases and ChemACXF have similar 
percentage values. The Accelrys database displays a very steep and narrow distri-
bution with a median between 1 and 2 and with 48 % of the compounds bearing 2 
hydrogen bond acceptors. By contrast, the other databases show a broad distribution 
with up to 12 H-bond acceptors for the ChemACXF database, but all with medians 
around 3. On average, the entities from the three latter databases have less accep-
tors than collections of pharmaceutically active compounds or drug collections with 
averages of 5 or more acceptors.13,15 
4.2.1.4 Number of hydrogen bond donors 
H-bond donors are also asymmetrically distributed with most entries bunched to-
wards low numbers (0 to 2 H-bond donors, Figure 4.2B). All databases show a very 
similar trend, but only the ChemACXF database contains molecules with up to 9 H-
bond donor atoms. Additionally, the ChemACXF database has lower cumulative per-
centage values than all other databases. Between 60 % (ChemACXF) and almost 
80 % (Accelrys, LeadQuest® Vol. 1-3) of the compounds have either 0 or 1 H-bond 
donors. These results agree well with the analysis of pharmaceutically active com-
pounds or drugs which have up to 3 times more frequently 0 to 2 than 3 to 5 H-bond 
donor atoms.13  
4.2.1.5 Number of rotatable bonds 
Both LeadQuest® databases follow a positively skewed distribution which is slightly 
displaced towards higher numbers of rotatable bonds and a median around 5 in the 
case of Vol. 1-3 whereas the median of Vol. 1&2 is at only 4 rotatable bonds (Figure 
4.3A). In principle, the Accelrys and ChemACXF databases are similarly distributed, 
but they contain more than 50 % and 15 % of all molecules with no rotatable bonds, 
respectively, and, in comparison to the LeadQuest® databases, also significantly 
higher percentages of compounds with nrot values of 1 and 2. Thus, molecules of 
both LeadQuest® databases are more drug-like than entities from the other data-
bases since most drugs and other pharmaceutically active compounds contain more 
than 5 rotatable bonds.13  
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Figure 4.2. Distribution of A) number of hydrogen bonding acceptors (nacc) and B) number of hydro-
gen bonding donors (ndon)  for LeadQuest® libraries Vol. 1&2 and Vol. 1-3, Accelrys, and ChemACXF 
databases. 
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Figure 4.3. Distribution of A) number of rotatable bonds (nrot) and B) number of rings (nring)  for 
LeadQuest® libraries Vol. 1&2 and Vol. 1-3, Accelrys, and ChemACXF databases. 
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4.2.1.6 Number of rings 
The distribution of the number of rings in the LeadQuest®, Accelrys and ChemACXF 
databases is illustrated in Figure 4.3B. Both LeadQuest® databases have medians 
between 2 and 3 rings whereas more than 60 % of the Accelrys entities contain no or 
just one ring. By contrast, around 80 % of all ChemACXF entities have 1 to 4 rings, 
nearly uniformly distributed. Drug-like molecules with a medium number of 3 to 5 
rings are frequent in the LeadQuest® databases. The ChemACXF database which is 
partly composed of drug molecules even contains 30 % of compounds with four 
rings.  
4.2.2 Property analysis of hits from LUDI runs 
The property analysis of all hits from the LeadQuest® and ChemACXF databases 
(chapter 3) in comparison to the distribution of the original databases should give 
insights into the capability of the programme LUDI to accumulate molecules meeting 
the LUDI-derived pharmacophore with similar (physico)chemical properties including 
ADMET and ‘drugability’. Interestingly, despite significantly different distributions of 
the original databases, the filtering process of the programme LUDI resulted in very 
similar distributions. As depicted in Figure 4.4A, the distribution of the molecular 
weights from both hit lists shows similar fractions of about 50 % for molecules from 
150 g/mol to 250 g/mol as well as from 250 g/mol to 350 g/mol, i.e. the distribution of 
the hit molecules is shifted towards lower molecular weights compared to the medi-
ans of the original databases. This result is contrary to other reports where database 
screening based on ‘potential of mean force’ (PMF) scoring16 and DOCK energy 
scoring17 has selected compounds with higher molecular weights. Apparently, both 
scoring schemes are unfavourable in this respect since an advantageous ADMET 
profile is more likely associated with a lower MW.18 A probable explanation for our 
results might be the successive LUDI compound selection procedure. Since energy 
scoring of the docked compounds is the most time-consuming process, each com-
pound scored has to pass a fast chemo-geometric filter allowing for chemical (H-
bond donor/acceptor) as well as geometrical matching which is solely determined by 
the search radius in the space of the enzyme’s active site. Thus, the following rule 
seems to apply: the smaller the search radius (at best about 5-6 Å, see chapter 3) 
the lower the molecular weight of the selected compounds. 
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A similar result was achieved for the XLOGP distribution of both hit lists (Figure 
4.4B). They follow a narrower Gaussian-like distribution with slightly higher percent-
age values compared to the original distributions. Additionally, the median of both 
distributions is shifted towards 3.5. Apparently, the filtering of the databases by LUDI 
extracts molecules with relatively similar lipophilicity, i.e. the simple LUDI pharma-
cophore (H-bond donor/acceptors and lipophilic centres) seems to reflect indispen-
sable properties of the hit molecules leading to a common XLOGP distribution inde-
pendent of the source of the compounds. 
With respect to the number of H-bond donor and acceptor atoms, both hit list distribu-
tions are very similar with 80 % of all hits having one donor and around 90 % having 
one to three acceptors, respectively (data not shown). This result is not surprising 
since the H-bond donor and H-bond acceptor interaction sites calculated by LUDI are 
well defined inside the search sphere and are preferentially included in the molecules 
by the algorithm. 
As depicted in Figure 4.5A, even the hit list distributions of the number of rotatable 
bonds in the molecules show a rather good agreement. Only the percentage of hits 
with no rotatable bond is significantly higher in the ChemACXF database (ca. 30%). 
Compared to the original distributions, the entities from both hit lists contain less ro-
tatable bonds. Such more rigid molecules are significantly enriched by the LUDI cal-
culation with cumulative percentage values for up to one rotatable bond of 50 to 55 % 
for the filtered vs. 9 % (LeadQuest® Vol. 1&2) and 29 % (ChemACXF) for the unfil-
tered databases. In contrast, the hit list distributions of the number of rings approxi-
mately reflect the percentage values of the original databases (Figure 4.5B). It might 
be suspected that a search sphere of 5-6 Å radius is large enough to ‘accommodate’ 
molecules with up to four rings which act as spacers bridging the H-bond donor or 
acceptor functionalities placed at the surface of the search sphere. Thus, the result-
ing hit list distributions should be directly related to those of the original databases.  
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Figure 4.4. Distribution of A) molecular weight (MW) and B) calculated logP value (XLOGP) for hit 
lists derived from LeadQuest® database Vol. 1&2 and ChemACXF database. For direct comparison, 
insets depict the distribution of the unfiltered databases. 
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Figure 4.5. Distribution of A) number of rotatable bonds (nrot) and B) number of rings (nring) for hit lists 
derived from LeadQuest® database Vol. 1&2 and ChemACXF database. For direct comparison, insets 
depict the distribution of the unfiltered databases. 
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4.3 Conclusions and summary 
With respect to drug-likeness, the distribution analysis of six (physico)chemical prop-
erties within four different databases revealed that both LeadQuest® databases pro-
vide a suitable basis for virtual screening purposes. Obviously, the further develop-
ment of the LeadQuest® database to Vol. 1-3 led to a compound selection which 
contains more drug-like molecules than its ancestor with respect to all examined 
properties except for molecular weight. Furthermore, the rather raw pre-filtering of a 
compound selection of commercially available molecules, the ChemACX database, 
by elimination of reactive compounds and of entities outside of a certain molecular 
weight range resulted in a database with property distributions significantly different 
from those of the LeadQuest® databases, though the physiochemical space well 
suited for a virtual screening database is covered. From the perspective of a medici-
nal chemist this point is of great significance since virtual screening projects may aim 
at drug molecules or at lead structures. Generally, hits are optimised during the me-
dicinal chemistry phase of a drug development process, but pre-optimisation of leads 
with respect to ‘drugability’ is also an appropriate approach.10 Thus, filtering of 
screening databases by means of raw (physico)chemical properties adapted from 
e.g. Lipinski’s ‘rules of 5´ provides an adequate basis for virtual screening. The prop-
erty analysis of the hit selections from the LeadQuest® and the ChemACXF data-
base, on the other hand, reflects the screening filter of the programme LUDI (the 
pharmacophoric properties of the enzyme’s binding site), leading to a restricted, al-
lowed pharmacological space represented by typical ranges of molecular weights, 
log P values, numbers of H-bond donor and acceptor atoms, and numbers of ro-
tatable bonds. These ranges are restricted with respect to the property distributions 
of the databases which should cover most of the ‘potential pharmacological space’. 
In conclusion, the property analysis of the databases used for de novo design of 
hyaluronidase inhibitors revealed that the LeadQuest® databases as well as the con-
structed ChemACXF database are at least comparable to the compound selections 
of pharmaceutical compounds and provide a robust basis for virtual screening with 
the programme LUDI. 
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4.4 Theoretical methods 
4.4.1 Preparation of the adapted ChemACX database 
The ChemACX database Version 5.5 comprising around 139000 molecules from 
different compound suppliers was purchased from CambridgeSoft Corporation 
(Cambridge, MA, USA). It was pre-filtered to remove salts, metals, and isotopes by 
means of ChemFinder Pro® Version 6.0 (CambridgeSoft Corporation, Cambridge, 
MA, USA). To eliminate very small molecules, e.g. solvents and rather large com-
pounds, the database was also filtered for molecular weights in the range of 
100 g/mol to 500 g/mol. Additionally, compounds with reactive functional groups like 
acyl halides, sulfonyl halides etc. as adapted from Oprea et al.13 (see Figure 4.6) 
were discarded using the substructure search function from ChemDraw Pro® Version 
6.0 (CambridgeSoft Corporation, Cambridge, MA, USA). The final adapted Chem-
ACX database consists of around 96000 2D structures. For the sake of clarity, we 
refer to the adapted ChemACX database as ChemACXF throughout the study. 
4.4.2 Processing of databases 
The ChemACXF database (96000 structures), the LeadQuest® databases Vol. 1&2 
and Vol. 1-3 (ca. 23000 and 60000 molecules, respectively4) were converted into 3D 
using the CONVERTER module from Insight 2000 (Accelrys Inc., San Diego, CA, 
USA). All-trans conformations of chains and chair conformations of 6-membered 
rings consisting of only sp3 atoms were adjusted to allow for energy minimum con-
formations of the resulting 3D structures. Additionally, two stereoisomers per stereo 
centre in each molecule were created if existing. By this procedure, 196908, 28717 
and 87095 molecules were generated for ChemACXF, LeadQuest® Vol. 1&2 and Vol. 
1-3 databases, respectively. The resulting databases were converted into the re-
spective input file formats with the SYBYL module DBTRANSLATE as required by 
the subsequently used software, e.g. LUDI or X-Score.  
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Figure 4.6. Molecules with reactive functional groups removed from the ChemACX Database V5.5. 
Modified from Oprea et al.13 
4.4.3 Descriptor analysis of databases 
The 3D versions of the ChemACXF database, the LeadQuest® databases Vol. 1&2 
and Vol. 1-3, and the Accelrys database as supplied in the LUDI module as well as 
the hit lists from the LeadQuest® database Vol. 1&2 and the ChemACXF database 
were analysed with respect to properties described by molecular connectivity follow-
ing an approach described by Oprea et al.13 Estimates of molecular weights, 
XLOGP,14 number of rings, hydrogen bond donors, hydrogen bond acceptors, and 
number of rotatable bonds were performed using a personally adapted version of the 
X-Score19 programme. The number of rings (nring) is evaluated using a bond-based 
algorithm.19 The numbers of hydrogen bond donors (ndon) and acceptors (nacc) are 
calculated on the basis of a look-up table of adapted Tripos atom types involved in 
hydrogen bonding that includes only nitrogen and oxygen atoms. Other donors, such 
as thiols, or acceptor atoms, such as halides, are ignored. Both variables are counted 
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separately, i.e. an O-H group can be both donor and acceptor. The number of rotors 
(nrot) implies acyclic sp3-sp3 or sp3-sp2 single bonds between two non-hydrogen at-
oms. In contrast to the originally implemented determination of nrot, sp2-sp2 rotors 
were included in the statistical analysis since the original programme neglects these 
rotors due to its rotor definition.19 
Property distributions were analysed by adding a module to the original X-Score 
code. This routine performs a histogram-type of analysis on large numbers of data, in 
a manner that can be user-defined (with respect to, e.g., the bin size). It counts the 
number of data points between the current bin and the adjoining higher bin. A value 
is counted in a particular bin if it is equal to, or less than the bin value down to the 
last bin limit. For integer variables (e.g., nrot, nring), results are displayed for the corre-
sponding values (bin counts for that particular integer value). A median is defined as 
the point where the sum of cumulative percentage values reaches 50 % of all data-
base entries. The data transformation and visualisation was done with Sigma Plot 8.0 
(SPSS Inc., Illinois, USA). 
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Chapter 5 Homology modelling of bovine testicu-
lar hyaluronidase and de novo design of ligands of 
bovine testicular hyaluronidase 
5.1 Introduction 
Computer aided drug design (CADD) has evolved into a substantial part of the drug 
discovery process over the last three decades. Nowadays, the application of CADD 
approaches accelerates the discovery of new lead compounds and their structural 
optimisation with respect to affinity and pharmacological properties (see chapter 3). 
The computer methods are developed to predict interactions between small organic 
compounds and macromolecular targets, mainly proteins and nucleic acids. In gen-
eral, the kind of approach depends on the availability of a three-dimensional (3D) 
structure of the biological target. If present, structure-based design is possible, oth-
erwise only ligand-based design methods may be applied.1  
Structure-based approaches are to design compounds which spatially fit to a binding 
site of the macromolecule by forming electrostatic, steric and hydrophobic interac-
tions. Two general cases of searching for such biologically active molecules may be 
discriminated: virtual screening (molecular database mining) and de novo ligand de-
sign combined with fast automated docking. Prerequisite of all virtual screening 
methods is the detailed knowledge about the localisation and the geometry of the 
binding site, mostly deduced from X-ray structures with co-crystallised natural sub-
strates or synthetic organic ligands. All screening and de novo design programmes 
like CAVEAT,2 TOPAS,3 LeapFrog,4 LUDI5 etc. derive a complex pharmacophore 
which accounts for specific steric and electrostatic interactions, hydrogen bond for-
mation and other factors relevant for ligand-protein binding. A large database of small 
organic, mostly drug-like molecules is screened to retrieve compounds meeting the 
pharmacophoric features. The predicted binding affinities of suitable candidates are 
ranked by an integrated scoring function for subsequent compound selection. In 
many cases, these approaches are accompanied by fast automated post-docking us-
ing FlexX,6 AutoDock,7 and DOCK8 etc.9  
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Ligand-based methods are applied if no structural information about the target and its 
ligand binding site, i.e. no crystal structure or no reliable homology model, is avail-
able. Based on the analysis of ligands with known biological activity, these methods 
include the design of pharmacophoric models10 by, e.g., the active analogue ap-
proach11, the analysis of quantitative structure-activity relationships (classical QSAR) 
and 3D-QSAR.12 Also pseudoreceptor models for screening are employed to dis-
cover lead compounds and/or to optimise known ligands.1 
For the design of mammalian hyaluronidase inhibitors, a structure-based strategy 
could be applied. A homology model of bovine testicular hyaluronidase (BTH) derived 
from crystal structures of the bee venom hyaluronidase13 as templates was accom-
plished with the help of the programme MODELLER.14-16 The bovine enzyme shows 
a satisfying sequence identity of ca. 30 % with respect to the bee hyaluronidase. 
Subsequently, potential BTH inhibitors were generated by the de novo design soft-
ware LUDI.5,17 Additionally, an ‘active analogue-like’ approach was applied for the 
design of BTH ligands starting from the superposition of the BTH binding site with 
similar sites of related chitinases in complex with their inhibitors. 
5.2 Results and discussion 
5.2.1 Homology modelling of bovine testicular hyaluronidase 
Homology modelling of BTH was the prerequisite for structure-based ligand design of 
mammalian hyaluronidase inhibitors. In consideration of the low, but significant 
amino acid sequence identity between insect and mammalian hyaluronidases, the 
crystal structure of bee venom hyaluronidase13 has provided the first possibility to 
construct reliable homology models of mammalian hyaluronidases like BTH. 
The homology modelling of BTH with MODELLER was based on a multiple sequence 
alignment of BTH and two templates, the human PH-20 protein and the bee venom 
hyaluronidase (see chapter 6), using ClustalW.18 Subsequently, a fully automated 
construction of a template-fitting BTH model was performed by MODELLER version 
6.2.14-16 The resulting structure was evaluated for correct local geometry and com-
pleted by addition of hydrogen atoms and energy minimisation (for more details see 
chapter 6). A schematic representation of the homology model of BTH is presented in 
Figure 5.1. Both catalytic residues Asp147 and Glu149 are located in the centre of 
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the wide HA binding crevice crossing the whole enzyme (yellow bow). Thus, both 
amino acids are rather solvent-exposed. 
5.2.2 Search for molecular fragments as bovine hyaluronidase inhibitors 
using the computer programme LUDI 
With the help of the de novo design programme LUDI, small and fairly rigid mole-
cules were retrieved from the 3D structure databases LeadQuest® Vol. 1-34 and 
ChemACXF (see chapter 3) by docking into the binding site of the homology model 
of BTH. LUDI estimates the expected binding affinity for each successfully docked 
ligand by an empirical scoring function.19 Using standard parameters for LUDI 
calculations, all 3D structures are treated as rigid bodies independent of the pres-
ence of rotatable bonds. 
The ligand-binding region of the enzyme where interactions are considered is repre-
sented by a sphere with a selectable radius. Based on a superposition of all Cα-at-
oms of the BTH homology model with the corresponding atoms of the crystal struc-
ture of bee venom hyaluronidase in complex with a hyaluronan (HA) tetrasaccharide 
fragment, the centre of the search sphere was defined by the coordinates of the car-
bon C3 of the N-acetylglucosamine monomer at the reducing end of the substrate. 
For all functional groups of the enzyme exposed to the binding region within a sphere 
radius of 6 Å, putative interaction sites in space were generated by LUDI according to 
rules which have been derived from composite crystal-field environments compiled 
with appropriate small molecule crystal data (Cambridge Structural Database).17 The 
programme tries to fit each database molecule onto these interaction sites.  
The most important amino acids within the search sphere of BTH and the pre-calcu-
lated interaction sites are shown in Figure 5.2. Next to both catalytic residues, the HA 
binding site is rather open and is dominated by several hydrophobic amino acids. 
The subsite*** -1 for the N-acetylglucosamine residue forms a small pocket defined by 
the tyrosines Tyr220, Tyr265 and Tyr305 as well as the tryptophan Trp341. The at-
tached subsite -2 for glucuronic acid is constituted by Tyr93 at the bottom as well as 
by Trp341 and Leu344 on either side. The LUDI H-bond acceptor interaction sites in 
                                            
***
 By convention, the sugar residue subsites are labelled from -n to +n, with -n at the non-reducing end 
and +n at the reducing end of the substrate. Cleavage occurs between the -1 and +1 subsites.20 
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the upper left part of Figure 5.2 reflect the backbone NH-group of Leu344 which inter-
acts with the carboxylic group of glucuronic acid. 
For the LUDI calculations, an accurate treatment of the protonation states of all resi-
dues inside the active site is important. Since both catalytic residues Asp147 and 
Glu149 are solvent-exposed, two different protonation patterns seemed to be possi-
ble a priori. In the crystal structure of BVH, the corresponding aspartate and gluta-
mate side chains (Asp111 and Glu113) are in close proximity − independent of an 
acidic or neutral pH used for crystallisation13 − forming a short hydrogen bond be-
tween both carboxylates. Therefore, Asp147 was always protonated in virtual 
screening runs. Glu149 probably acts as the proton donor during HA hydrolysis.13 
This switching implies that Glu149 must be treated in both protonisation states in 
different LUDI approaches. 
Performing LUDI runs with the constructed LeadQuest® database Vol. 1-3 resulted in 
257 and 175 hits with charged and uncharged Glu149, respectively, ranked on a 
relative scale by their expected binding affinity according to the scoring function de-
scribed by Böhm.19 The numbers of hits retrieved from the ChemACXF database 
were 4030 (Glu149 charged) and 1339 (Glu149 uncharged). Five of the proposed 
hits were selected for testing hyaluronidase inhibition according to high LUDI scores, 
availability and efficient synthetic feasibility. 
 
Figure 5.1. Schematic representation of the BTH model. α-helices and β-sheets are depicted in purple 
and yellow, respectively. The hyaluronan binding region and both catalytic residues are shown explic-
itly. 
E149 
D147 
HA binding region 
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Figure 5.2. Interaction sites generated by LUDI with a sphere radius of 6 Å inside the active site of the 
BTH model (white, lipophilic sites; red, hydrogen bond acceptors, blue, hydrogen bond donors). 
As shown in Table 5.1, none of the investigated compounds induced an inhibition of 
BTH except compound 4, which displayed with very weak partial inhibitory activity of 
the enzyme (by 10 % at maximal test concentration). All compounds were also in-
vestigated for their inhibitory potencies on hylB4755. Surprisingly, compounds 1, 2 and 
5 partially inhibited the activity of this bacterial hyaluronidase. The results for the first 
two structures were the starting point of an extended investigation of substituted in-
doles and indolines as hyaluronate lyase inhibitors which led to the identification of 
several indole derivatives with inhibitory activities on hylB4755 in the lower micromolar 
concentration range.21 
In general, most of the investigated compounds were poorly soluble, thus complicat-
ing the identification of BTH inhibitors since lead compounds are commonly active 
only in the submillimolar to millimolar concentration range. Additionally, not all of the 
potential H-bond acceptor and H-bond donor interaction sites present in the search 
sphere inside the active site of BTH are adopted by the hits. Most of the compounds 
selected by LUDI are rather lipophilic, i.e. their lipophilic score fractions clearly domi-
nate their total scores. Also very few of the proposed molecules dunk into the pocket 
of subsite -1 and, simultaneously,  form hydrogen bonds with the catalytic residues 
as well as with Leu344 (data not shown). Thus, the probably most important and 
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specific interactions of the amphiphilic HA substrate in the bee venom hyaluronidase 
complex13,22 are not reproduced by the majority of the hits. In general, the probablility 
of finding leads ranges from 1 per mill to 1 % depending on the target of interest. In 
many cases, the virtual screening approach significantly increases the hit rate, but 
still a substantial number of compounds has to be screened for biological activtiy. 
Thus, due to statistical reasons, more than only five compounds should have been 
investigated for inhibitory activity on BTH. 
Therefore, the results from the LUDI calculations will be used only to further optimise 
compounds for hylB4755 inhibition. For BTH inhibitors, an alternative ligand-based ap-
proach is presented in the next section. 
Homology modelling of BTH and de novo design of ligands of BTH
 
 77
Table 5.1. Inhibitory activities of selected compounds on BTH and hylB4755.  
No Structure BTH hylB4755 
  (% inhibition)a 
  pH 5.0 pH 5.0 
1 NN
 
inactive 
(≤ 3 mM) 
37 % 
(3 mM) 
2 N
S
 
inactive 
(≤ 200 µM) 
30 % 
(200 µM) 
3 N
S
 
inactive 
(≤ 4.5 mM) 
50 % 
(4.5 mM) 
4 CNHNS
Cl
O
O
 
10 % 
(400 µM) 
30 % 
(400 µM) 
5 SN
N
 
inactive 
(≤ 1.6 mM) 
25 % 
(1.6 mM) 
          a
 % inhibition of enzyme at indicated inhibitor concentration (n=3; error not larger than 1 %) 
In addition, all compounds which had been selected as inhibitors of S. agalactiae 
strain 4755 hyaluronidase from the LUDI approaches described in chapter 3 were 
tested for BTH inhibition. Among these hylB4755 hits, three compounds proved to be 
moderate to good inhibitors of the bovine testicular hyaluronidase. 1-Furan-2-yl-3-(4-
nitrophenyl)propenone (6) and indole-2-carboxylic acid (7) induced a concentration-
dependent inhibition with an IC50 value of 4 mM and 7 mM, respectively. The most 
active compound of this set was 1,3-diacetylbenzimidazole-2-thione (8) which inhib-
ited the BTH activity with an IC50 value of 250 µM.23 This result prompted us to fur-
ther investigate derivatives of 823 as well as compounds 9 and 10 which were re-
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trieved as BTH hits from the ChemACXF database by LUDI. These investigations are 
part of ongoing work. 
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Figure 5.3. Chemical structures of BTH inhibitors 6-8 identified by LUDI calculations on hylB475523 and 
BTH hits 9 and 10 from the ChemACXF database. 
5.2.3 Ligand-based design of inhibitors of bovine testicular hyaluroni-
dase 
Elucidation of the crystal structure of bee venom hyaluronidase revealed an unusual 
fold of an open 7-stranded (β/α)-barrel. By using the DALI server 
(http://www.ebi.ac.uk/dali/) for the detection of similarly folded proteins, the crystal 
structure of the bacterial chitinase A (ChiA) from Serratia marcescens (pdb code: 
1ctn) was identified.13 The active sites of both enzymes are closely related. Recently, 
the crystal structure of chitinase A in complex with the inhibitor allosamidin (11) could 
be elucidated.24 Allosamidin is produced by Streptomyces sp.25 and consists of two 
β-1,4-linked N-acetylallosamine rings and one allosamizoline (an oxazoline deriva-
tive). The allosamizoline part of the inhibitor binds to the subsite -1 of the chitin bind-
ing site24 – equivalent to subsite -1 of the hyaluronan binding site at mammalian 
hyaluronidases – and probably mimics the covalent intermediate 12 of the N-acetyl-
glucosamine residue (Figure 5.4) during hydrolysis like suggested for several chiti-
nases.26-28 
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Figure 5.4. Chemical structures of chitinase inhibitor allosamidin (11), the proposed hydrolysis 
intermediate of N-acetylglucosamine residue 12, the derived BTH inhibitor 13 and chitinase B (ChiB) 
inhibitor CI-4 (14) as well as the suggested BTH inhibitor 15. 
The five equivalent amino acids of the active sites of the BTH model, the crystal 
structure of bee venom hyaluronidase in complex with a HA tetrasaccharide fragment 
(pdb code: 1fcv), and the X-ray structure of chitinase A complexed with allosamidin 
(pdb code: 1ffq) are closely superimposed (see Figure 5.5A). Surprisingly, the N-
acetylglucosamine residue of HA also overlaps with the allosamizoline moiety of the 
chitinase inhibitor. The 3-hydroxy group of allosamizoline aligns with the anomeric 
oxygen of D-glucuronic acid (Figure 5.5B). Therefore, with respect to hyaluronidase 
inhibitor design, a substitution in position 3 of allosamizoline with β-D-glucuronic acid 
(comparable to its position found in the HA tetrasaccharide fragment) is suggested. 
The topology of compound 13 (Figure 5.4) combining an allosamizoline moiety, pro-
posed to mimic a catalytic intermediate, with glucuronic acid is compatible with bind-
ing to bee venom hyaluronidase and probably also to BTH (Figure 5.5B). 
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Figure 5.5. A) Superposition of active site residues of BTH model (yellow), BVH crystal structure (pur-
ple) and ChiA crystal structure as specified in section 5.4.4. The amino acid Tyr220 (BTH) and its 
equivalents Tyr184 (BVH) and Met388 (ChiA) are shown additionally but were not included in the su-
perposition procedure. B) Overlap of corresponding fragments of HA (C atoms coloured in orange, O 
atoms coloured in red) and allosamidin (coloured by atom types) as resulting from the superposition in 
Figure 5.5A. As reference, active site residues of BTH model are shown in yellow. For sake of clarity, 
not all parts of the co-crystallised ligands are depicted. 
 
Figure 5.6. A) Superposition of active site residues of ChiA (green) and ChiB (cyan) crystal structures 
with complexed allosamidin (C atoms grey, other atoms by atom type) and CI-4 (C atoms orange, 
other atoms by atom type), respectively. B) Superposition of active site residues of BTH model (yel-
low) and ChiB crystal structure with complexed CI-4 (atoms by atom type). HA disaccharide fragment 
(C atoms orange, O atoms red) was extracted from the BVH-HA complex with coordinates from su-
perposition of the active sites of BTH, BVH and ChiB.  
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Extensive investigations of various allosamidin derivatives as chitinase A inhibitors 
revealed that allosamizoline itself is only a moderate inhibitor with an IC50 value of ca. 
0.2 mM29 despite its good fit into the pocket of subsite -1 in the complex of ChiA with 
allosamidin.24 Additionally, an allosamidin derivative truncated by one sugar unit 
proved to be almost as potent as allosamidin itself.29 Due to the highly similar active 
site, allosamizoline should inhibit BTH too, but also in this case with low potency in 
the submillimolar concentration range. Consequently, compound 13 might fulfil 
structural conditions necessary for inhibitory activity on BTH at micromolar concen-
tration. 
Recently, the cyclic dipeptide CI-4 [14, cyclo-(L-Arg-D-Pro)], identified to weakly in-
hibit chitinase B (ChiB) from Serratia marcescens,30 has been co-crystallised with this 
enzyme.31 After superposition of the active site residues of ChiA and ChiB, the cyclic 
CI-4 dipeptide backbone is situated in the same hydrophobic pocket (subsite -1) as 
the allosamizoline moiety of allosamidin (Figure 5.6A). Additionally, the arginine side 
chain fits to the same region like the N-acetylallosamine substructure in ChiA and like 
the D-glucuronic acid monomer in subsite -2 of BVH (Figure 5.6A,B).  
Based on the superposition of CI-4 and the HA disaccharide fragment (Figure 5.6B), 
compound 15, a cyclic peptide composed of D-proline and L-2-aminoadipic acid, is 
proposed. The cyclic dipeptide backbone of 15 might structurally mimic the afore-
mentioned intermediate and might similarly interact with Tyr265 and Glu149 as sug-
gested for CI-4 with the corresponding amino acids Tyr214 and Glu144 of ChiB.31 
The arginine side chain of CI-4 is not involved in direct interactions with amino acids 
of the active site of ChiB31 and may therefore be exchanged by other, more suitable 
moieties. Since the guanidine of Cl-4 aligns with the carboxylic group of D-glucuronic 
acid of the HA disaccharide fragment (Figure 5.6B), arginine may be well replaced by 
L-2-aminoadipic acid. In conclusion, compound 15 is expected to be a potent inhibitor 
of BTH due to putative interactions derived from HA. 
5.3 Summary 
A homology model of bovine testicular hyaluronidase based on crystal structures of 
bee venom hyaluronidase was constructed with the help of MODELLER and used for 
de novo design of BTH inhibitors with the programme LUDI. Filtering of the Lead-
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Quest® databases Vol. 1-3 and the ChemACXF database resulted in more than 5500 
hits. According to high LUDI scores, availability and synthetic feasibility, five com-
pounds were selected for testing hyaluronidase inhibition. Unfortunately, none of the 
compounds inhibited BTH, probably due to their poor solubility. 
To possibly overcome this failure a search for less lipophilic compounds was per-
formed by an additional, ligand-based approach. The superposition of the active sites 
of the BTH model with the crystal structures of bee venom hyaluronidase and the 
chitinases A and B revealed a very good overlap of the amino acids involved in ca-
talysis and of the co-crystallised ligands (HA tetrasaccharide fragment, allosamidin 
and CI-4). By considering essential substructures mimicking the proposed intermedi-
ate of HA hydrolysis and by introducing suitable substituents suggested to interact 
with amino acid of the active site, compounds 13 and 15 were proposed as potential 
BTH inhibitors. The synthesis and biochemical investigations of these compounds 
are part of ongoing work. 
5.4 Theoretical methods 
All calculations were done on a SGI OCTANE R10000 workstation. 
5.4.1 BTH model construction 
The homology modelling of bovine testicular hyaluronidase (BTH) is described in 
detail in chapter 6.  
5.4.2 LUDI calculations with the BTH model 
A LUDI approach was set up with a sphere of 6 Å radius in the space of the active 
site of the BTH model. To determine the centre of this sphere, the BTH model and 
the crystal structure of bee venom hyaluronidase in complex with a HA fragment (pdb 
code: 1fcv) were superimposed by using the Cα-atoms of corresponding amino ac-
ids. The coordinates of the carbon atom C3 of the sugar monomer N-acetylglucosa-
mine in subsite††† -1 were taken as centre of the search sphere. The values of the 
                                            
†††
 By convention, the sugar residue subsites are labelled from -n to +n, with -n at the non-reducing 
end and +n at the reducing end of the substrate. Cleavage occurs between the -1 and +1 subsites.20 
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most important LUDI parameters for design of BTH ligands were as follows: the 
maximal rms deviation of the fit between the fragments and the interaction sites was 
0.45 Å, the density of lipophilic and polar interaction sites per protein atom was set to 
25 and the minimal contact surface between ligand and protein was set to 30 %. The 
retrieved candidate molecules were ranked with respect to their expected binding 
affinity using the empirical scoring function developed by Böhm32 with a minimal scor-
ing value of 300 (predicted Ki value of 1 mM). All other parameters were set to default 
values. The ambiguous protonisation state of the catalytic residue Asp149 is consid-
ered by performing two separated LUDI calculations (charged and uncharged 
Glu149, respectively). 
LUDI runs with the constructed LeadQuest® database Vol. 1-3 resulted in 257 and 
175 hits for Glu149 and uncharged Glu149, respectively. The number of hits from the 
ChemACXF database was 4030 and 1339 for Glu149 and uncharged Glu149, re-
spectively. Of the proposed hits five compounds were selected for testing hyaluroni-
dase inhibition according to high LUDI scores, availability and efficient synthetic fea-
sibility. 
5.4.3 Determination of the inhibitory effects of the test compounds 
The inhibitory effects of the test compounds on the hyaluronidase from bovine testis 
were measured using a turbidimetric assay according to the description of Di Fer-
rante.33 Details are given in chapter 6. 
5.4.4 Ligand-based design by superposition of X-ray structures of re-
lated enzymes complexed with inhibitors  
Putative inhibitors of BTH could be suggested by superimposing the BTH model and 
the crystal structure of bee venom hyaluronidase with crystal structures of bacterial 
chitinases sharing similar active site architectures.13,22 The following corresponding 
amino acids of the active sites were superimposed (see Table 5.2). 
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Table 5.2. Active site amino acids selected for superposition of hyaluronidases and 
chitinases complexed with ligands. 
enzyme  superimposed amino acids   pdb 
code 
ligand 
BTH1 
 
Tyr93 Asp147 Glu149 Tyr265 Trp354 
 
model none 
BVH 
 
Tyr55 Asp111 Glu113 Tyr227 Trp309 
 
1fcv 
HA 
fragment 
ChiA2 
 
Phe191 Asp313 Glu315 Tyr390 Trp539 
 
1ffq 
allos-
amidin3 
ChiB2 
 
Phe51 Asp142 Glu144 Tyr214 Trp403 
 
1o6i CI-43 
1
 Amino acid sequence according to Meyer et al.34 
2
 Chitinase A (ChiA) and chitinase B (ChiB) from Serratia marcescens. 
3
 Chemical structures are depicted in Figure 5.4. 
By superimposing all complexed structures, the HA fragment, allosamidin as well as 
CI-4 show a common overlap at the binding subsite -1 of the N-acetylglucosamine 
monomer of hyaluronan. Since substructures of allosamidin and CI-4 mimic the pos-
tulated intermediate of the N-acetylglucosamine moiety (12), the combination of 
these mimicking moieties and the introduction of substituents suggested to interact 
with amino acids of the active site of BTH led to the prediction of two BTH inhibitors 
(see Figure 5.4). 
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Chapter 6 L-ascorbic acid-6-hexadecanoate as po-
tent hyaluronidase inhibitor: structural elucidation 
and molecular modelling of enzyme-inhibitor com-
plexes  
6.1 Introduction 
The glycosaminoglycan hyaluronic acid (HA), consisting of repeating disaccharide 
units of (β-1,4)-D-glucuronic acid-(β-1,3)-N-acetyl-D-glucosamine, is a major compo-
nent of the extracellular matrix of all mammalian tissues. It occurs in significant quan-
tities in the skin (dermis and epidermis), brain, and central nervous system1 and is 
also present in some bacteria. HA is the common substrate of a class of enzymes 
termed hyaluronidases (for a review see http://www.glycoforum.co.jp). The enzymes 
from bacterial sources are endo-N-acetyl-glucosaminidases (hyaluronate lyases, EC 
4.2.2.1).2,3 Their proposed catalytic mechanism4-7 has been firmly supported by 
successive structural determinations4,8-10 and mutagenesis studies.8,9,11 Main 
degradation products are unsaturated disaccharides or tetrasaccharides which might 
be utilised as an additional carbon source.12 More probably, the degradation of HA 
decreases the viscoelasticity of the extracellular matrix leading to increased spread-
ing of the bacteria and the toxins in the tissue.12 
The other group of hyaluronidases, with the bovine testicular hyaluronidase or bovine 
PH-20 protein as well-known representative, are present in vertebrate tissues as well 
as in the venom of bees, wasps, etc. and act as endo-N-acetyl-glucosaminidases 
(hyaluronate glycanohydrolases, EC 3.2.1.35 and EC 3.2.1.36).2,13 In contrast to the 
bacterial enzymes, the human enzymes PH-20 protein, Hyal114 and Hyal2 probably 
exist in several isoforms. To date, six human hyaluronidases have been cloned15 and 
expressed in different cell lines, but no larger amounts of the enzymes could be pro-
duced for enzymological investigation. As the only exception, the crystal structure of 
the distantly related bee venom hyaluronidase could be elucidated.16 The mammalian 
enzymes like PH-20 protein, Hyal1 and Hyal2 seem to be involved in physiological 
and pathophysiological processes like fertilisation,17 embryonic development,18 tu-
mour growth and metastasation,19 but the specific functions of HA and hyaluroni-
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dases within these processes remain obscure up to now. Therefore, hyaluronidase 
inhibitors are needed as pharmacological tools to study the physiological and patho-
physiological role of HA and HA degrading enzymes. Moreover, hyaluronidase in-
hibitors could be useful as drugs, e.g. in the treatment of arthroses or, combined with 
antibiotics, in antibacterial therapy.  
Heparin,20 flavonoids21 and fully O-sul-
fonated glycosaminoglycanes22,23 were 
reported to inhibit bovine testicular hya-
luronidase (BTH) in vitro, but these 
compounds show only weak or partial 
inhibitory activity.24 For the bacterial hya-
luronidase from S. pneumoniae 
(hylSpn), guanidine hydrochloride, NG-nitro-L-arginine methyl ester, L-arginine25 and 
vitamin C (1, Figure 6.1,26) were described as inhibitors with IC50 values from 150 
mM to 0.15 mM. Thus, no potent and selective hyaluronidase inhibitors have been 
characterised to date. 
Recently, the structural basis of the hylSpn-L-ascorbic acid interaction could be elu-
cidated by means of X-ray crystallography.26 Most regions of 1 bind inside the active 
site via hydrophobic interactions with two residues, Trp292 and Tyr408. Thus, in-
creased hydrophobicity of vitamin C derivatives might lead to higher inhibitory activ-
ity. To prove this hypothesis, L-ascorbic acid-6-hexadecanoate (2), a highly effective 
antioxidant27 and glutathione-S-transferase inhibitor,28 was examined as potential 
inhibitor of two bacterial hyaluronidases from S. pneumoniae and S. agalactiae strain 
4755 and of bovine testicular hyaluronidase as solely available representative of 
mammalian hyaluronidases. Additionally, the crystal structure of S. pneumoniae 
hyaluronate lyase (hylSpn), co-crystallised with 2, was determined at 1.65 Å resolu-
tion to examine the protein-L-ascorbic acid-6-hexadecanoate interactions at the mo-
lecular level. For possible conclusions with respect to the topology of mammalian 
hyaluronidases, a homology model of BTH based on the crystal structure of bee 
venom hyaluronidase in complex with a HA tetrasaccharide fragment was con-
structed. In comparison to the hylSpn-L-ascorbic acid-6-hexadecanoate complex, the 
potential binding mode of 2 at BTH was predicted by flexible docking. Results and 
conclusions from these approaches should help to develop improved binding models 
for further, more potent and selective hyaluronidase inhibitors.  
OH
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1    H
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Figure 6.1. Chemical structures of L-
ascorbic acid (1) and L-ascorbic- acid-6-
hexadecanoate (2) 
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6.2 Results and discussion 
6.2.1 Comparison of inhibitory activities of L-ascorbic acid and L-ascor-
bic acid-6-hexadecanoate on hyaluronidases 
Recently, the inhibitory activities of L-ascorbic acid (1) on S. pneumoniae hyaluronate 
lyase (hylSpn) and bovine testicular hyaluronidase (BTH) have been investigated. L-
Ascorbic acid induced an inhibition of hylSpn with an IC50 value of around 6 mM un-
der the reaction conditions used, but no activity could be observed on BTH.26 
Probably due to the specific HA degradation mechanism of bovine testicular hyalu-
ronidase, the usual colourimetric assay based on the Morgan-Elson reaction results 
in another pH activity profile than a turbidimetric assay.29 Therefore, to normalise the 
experiments among all three enzymes, the turbidimetric assay with equiactive con-
centrations of all enzymes was applied. In accordance with the aforementioned high 
IC50 value, the bacterial enzymes were weakly inhibited by vitamin C (1) with 
IC50 values of 6 mM for hylB4755 and 32 mM for hylSpn, respectively, whereas the 
bovine enzyme was not affected up to 100 mM. Therefore, vitamin C proved to be a 
weak, but selective inhibitor of streptococcal hyaluronate lyases. 
The crystal structure of the bacterial hyaluronate lyase-vitamin C complex26 sug-
gested which structural variations might lead to stronger inhibitors of the enzyme. 
Due to the presence and topology of hydrophobic residues in the catalytic cleft,26 the 
introduction of lipophilic chains in position 6 of vitamin C like in L-ascorbic acid-6-
hexadecanoate (2) has promise. Hydrophobic interactions also play an important role 
for the substrate HA since it has a two-fold helix as secondary structure in aqueous 
solutions with an extensive hydrophobic patch (about 8 CH units, roughly corre-
sponding in size to octanoic acid). Thus, hyaluronic acid combines hydrophilic re-
gions with hydrophobic patches, both characteristic of lipids.30  
As a consequence of these suggestions, the effects of compound 2 on the hyaluro-
nate lyases and on the bovine testicular hyaluronidase were determined. 
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Figure 6.2. Enzyme activity of hylB4755, BTH and hylSpn in the presence of L-ascorbic acid-6-hexa-
decanoate (2). The L-ascorbic acid-6-hexadecanoate concentration range was 1.1–300 µM. The inhi-
bition of the enzyme activity by compound 2 is presented in a sigmoidal concentration-dependent 
manner with 50 % inhibition (IC50) as shown in Table 6.1. 
Compound 2 induced a potent inhibition of hylB4755 with an IC50 value of 4 µM, as 
illustrated in Figure 6.2. Equiactive concentrations of hylSpn and bovine testicular 
hyaluronidase resulted in IC50 values of 100 µM and 56 µM, respectively. L-Ascorbic 
acid-6-hexadecanoate is thus up to 1500 times more active than vitamin C (Table 
6.1) and proved to be the most potent inhibitor of bacterial and bovine hyaluroni-
dases described to date. 
L-Ascorbic acid-6-hexadecanoate exhibits about 25-fold, but vitamin C (1) only 6-fold 
higher inhibitory activity on hylB4755 compared to hylSpn. This apparent selectivity of 
compound 2 for hylB4755, which cannot be quantitatively verified without knowledge 
about the individual Km values of the HA substrate used, requires further investiga-
tions. In contrast to L-ascorbic acid, overall selectivity of L-ascorbic acid-6-hexa-
decanoate for the bacterial enzymes vs. BTH could not be observed (Table 6.1).  
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Table 6.1. IC50 values (50 % inhibition of equiactive enzyme concentrations) ± SEM (n=4) on S. 
pneumoniae hyaluronate lyase, S. agalactiae hyaluronate lyase strain 4755 and BTH for vitamin C (1) 
and L-ascorbic acid-6-hexadecanoate (2). 
Inhibitor 
Enzyme 
Vitamin C 
IC50 (µM) 
L-ascorbic acid-6-hexa-
decanoate 
IC50 (µM) 
hylSpn 34800 ± 300 100.0 ± 2.00 
hylB4755 6100 ± 100 4.2 ± 0.13 
BTH inactive (≤ 100 mM) 56.5 ± 0.13 
 
The strikingly better inhibition of all investigated enzymes by L-ascorbic acid-6-hexa-
decanoate compared to vitamin C supports the working hypothesis that the long alkyl 
chain increases the affinity of the molecule by additional hydrophobic interactions 
with the enzyme. 
6.2.2 The binding mode of vitamin C hexadecanoate to S. pneumoniae 
hyaluronidase 
X-ray crystallography of the co-crystallised L-ascorbic acid-6-hexadecanoate-hylSpn 
complex was used for the determination of the binding mode. This information should 
be useful to deduce a model for the interactions of the inhibitor with amino acid resi-
dues inside the active site of the enzyme and should facilitate the further develop-
ment of more potent inhibitors. In cooperation, crystallisation experiments were ac-
complished by M. Nukui and M. J. Jedrzejas (Children's Hospital Oakland Research 
Institute, Oakland, California 94609, USA). The X-ray structure of the complex was 
solved by D. Rigden (National Center of Genetic Resources and Biotechnology, Ce-
nargen/Embrapa, Brasília, D.F. 70770-900, Brazil). 
The density at the binding site allowed for the satisfactory modelling of 2 as shown in 
Figure 6.3. In the final model, additional difference density and elevated B-factors of 
the inhibitor (Table 6.2) suggest remaining flexibility and alternative binding modes of 
2. However, despite repeated attempts, only the conformation shown was well sup-
ported by density. Surprisingly, no support for a lactone ring was evident from elec-
tron density, although the vitamin C moiety of the inhibitor binds to the same region 
as intact vitamin C.26 Obviously the vitamin C portion of the inhibitor binds in a ring-
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opened form emerging under the terms of crystallisation (Figure 6.3). It is known that 
oxidation of 1 gives L-dehydroascorbic acid which is rapidly degraded under physio-
logical conditions (pH 7.4) via L-diketogulonate to yield L-erythrulose and oxalate.31 
Possibly compound 2 is modified in a similar manner, but only the hydrolysed lactone 
moiety was modelled into the electron density (Figure 6.3). It is however unlikely that 
ring-opening also occurs during the enzymatic assay. 
 
Figure 6.3. The binding site of L-ascorbic acid-6-hexadecanoate. Hydrogen bonds are shown as dot-
ted lines and final sigmaA-weighted |2Fo-Fc| map electron density is shown, contoured at 0.9. 
The proposed catalytic mechanism of hylSpn4-7 has been firmly supported by succes-
sive structural determinations4,8-10 and mutagenesis studies.8,9,11 Catalysis occurs at 
the most narrow part of the catalytic cleft and involves residues Asn349, His399 and 
Tyr408. In addition, a hydrophobic patch consisting of Trp291, Trp292 and Phe343 
contributes to precise positioning of the substrate. As shown in Figure 6.3, compound 
2 binds within the catalytic site explaining the competitive inhibition. Figure 6.3 also 
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illustrates that the majority of protein-inhibitor interactions are hydrophobic, the only 
exceptions being a hydrogen bond between the carboxylic group of the inhibitor and 
the side chain hydroxyl of Tyr408, which acts as catalytic acid on HA cleavage,6 and 
another one between the hydroxy group at C5 and Asn290. The hydrophobic face of 
the vitamin C portion is flatly aligned with the side chain of Trp292 as part of the hy-
drophobic patch. Such an arrangement is commonly observed in complexes of 
carbohydrate binding proteins with their ligands.32 The palmitoyl moiety fits in a 
mainly hydrophobic surface crevice. The aliphatic chain is well-defined by density 
with the exception of the three terminal carbon atoms, for which missing density did 
not permit modelling. Hydrophobic interactions are formed with Trp291 and Phe343, 
both contributing to the hydrophobic patch along with His399 and Thr400. Figure 
6.4A,B compares the binding mode of 2 with that of a substrate-based hexasaccha-
ride (PDB code 1loh;33). The binding sites overlap, but the surface which accomo-
dates the palmitoyl group is not directly involved in substrate binding. Interestingly, 
one of the three well-ordered cryoprotectant xylitol molecules bound to hylSpn fits 
close to the end of the palmitoyl moiety. The distance between the penultimate visu-
alised carbon of the palmitoyl group and atom O5 of xylitol is only 4.0 Å (Figure 
6.4B). This position of the bound xylitol suggests that the affinity of the present inhibi-
tor might be enhanced through addition of matching groups at the aliphatic end of the 
palmitoyl moiety. 
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Figure 6.4. Comparison of binding modes of A) hexasaccharide substrate and B) vitamin C-6-hexa-
decanoate inhibitor. The protein surface is shown semi-transparently in order to enable three key 
catalytic residues (labelled) to be seen. The nearby cryoprotectant xylitol molecule (see text) is shown 
towards the lower right of B). 
6.2.3 Homology model of bovine testicular hyaluronidase as basis for 
the prediction of inhibitor binding modes  
For the prediction of the binding mode of L-ascorbic acid-6-hexadecanoate to BTH by 
flexible ligand docking, homology modelling was used. In consideration of the low, 
but significant amino acid sequence identity between insect and mammalian hyalu-
ronidases, the crystal structure of bee venom hyaluronidase16,34 has provided the first 
possibility to construct reliable comparative models of mammalian hyaluronidases, 
like BTH, human PH-20 protein and Hyal1-4. In the case of less than 40 % identity 
the correct sequence alignment is the most important factor affecting the quality of 
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the resulting models.35 Given that the sequence identity between BTH and bee 
venom hyaluronidase is just 32 % an improvement could be obtained by constructing 
a multiple – instead of a pairwise – alignment of BTH, human PH-20 protein and the 
bee venom hyaluronidase using ClustalW.36 
The functional analysis of mutants of the related human sperm PH-20 protein37 indi-
cated two catalytic acidic amino acids corresponding to BVH Asp111 and Glu113 
which were indeed shown to be involved in catalysis38 by exploring the binding region 
of the HA tetrasaccharide co-crystallised with bee venom hyaluronidase (pdb code: 
1fcv;16). Further analysis of the crystal structures and the multiple sequence align-
ment clearly show that the residues forming the active site of hyaluronidases are 
highly conserved (Figure 6.5). Thus, appropriate homology models will be most reli-
able in regions where competitive inhibitors bind. A fully automated construction of a 
comparative BTH model was performed using MODELLER version 6.2.39-41 The 
resulting structure was evaluated for correct local geometry by PROCHECK,42,43 by 
the SYBYL module ProTABLE and by comparison of the Ramachandran plot with 
that of the template (1fcq), and was completed by addition of hydrogen atoms and 
energy minimisation. 
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                 β1                α1                  β2         β2        β2    
             |         |         |         |         |         |         |          
BTH       48 SFLWAWNAPVERCVNRRFQLPPDLRLFSVKGSPQKSATGQFITLFYGDRLGYYPHIDEKTG---KTVFGG 
hPH-20    13 PFLWAWNAPSEFCLG-KFDEPLDMSLFSFIGSPRINATGQGVTIFYVDRLGYYPYIDSITG---VTVNGG 
BVH       10 EFNVYWNVPTFMCHKYGLRFEEVSEKYGILQNWMDKFRGEEIAILYDP--GMFPALLKDPNGNVVARNGG 
              *   ** *   *                         *      *    *  *              ** 
 
                      α2                   β3                     α3                
             |         |         |         |         |         |         |          
BTH      115 IPQLGNLKSHLEKAKNDIAYYIPNDSV-GLAVIDWENWRPTWARNWKPKDVYRDESVELVLQKNPQLSFP 
hPH-20    79 IPQKISLQDHLDKAKKDITFYMPVDNL-GMAVIDWEEWRPTWARNWKPKDVYKNRSIELVQQQNVQLSLT 
BVH       78 VPQLGNLTKHLQVFRDHLINQIPDKSFPGVGVIDFESWRPIFRQNWASLQPYKKLSVEVVRREHPFWDDQ 
              **   *  **           *        *** * ***    **     *   * * *           
 
                   α4                        β4                         α5       α6 
             |         |         |         |         |         |         |          
BTH      184 EASKIAKVDFETAGKSFMQETLKLGKLLRPNHLWGYYLFPDCYNHNYNQPTYNGNCPDVEKRRNDDLDWL 
hPH-20   148 EATEKAKQEFEKAGKDFLVETIKLGKLLRPNHLWGYYLFPDCYNHHYKKPGYNGSCFNVEIKRNDDLSWL 
BVH      148 RVEQEAKRRFEKYGQLFMEETLKAAKRMRPAANWGYYAYPYCYNLTPNQP--SAQCEATTMQENDKMSWL 
                  **  **  *  *  ** *  *  **   ****  * ***     *     *       **   ** 
 
                   β5                 α7                     β6  β6        β6     
             |         |         |         |         |         |         |          
BTH      254 WKESTALFPSVYLNIRLKSTQNAALYVRNRVQEAIRLSK--IASVESPLPVFVYARPVFTDGSSTYLSQG 
hPH-20   218 WNESTALYPSIYLNTQ-QSPVAATLYVRNRVREAIRVSK--IPDAKSPLPVFAYTRIVFTDQVLKFLSQD 
BVH      216 FESEDVLLPSVYLRWN-LTSGERVGLVGGRVKEALRIARQMTTSRKKVLPYYWYK---YQDRRDTDLSRA 
                   * ** **             *  ** ** *            **   *      *     **   
 
                 α8          β7               α9         α10  
             |         |         |         |         |         |   
BTH      322 DLVNSVGEIVSLGASGIIMWGSLNLSLSMQSCMNLGTYLNTTLNPYIINVTL / 
hPH-20   285 ELVYTFGETVALGASGIVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTL / 
BVH      282 DLEATLRKITDLGADGFIIWGSSDDINTKAKCLQFREYLNNELGPAVKRIAL  
              *         *** *   **          *     *    * *         
Figure 6.5. Sequence alignment of bovine testicular hyaluronidase (BTH), human PH-20 
protein and bee venom hyaluronidase (BVH) as the basis of homology modelling with 
MODELLER 6.2. -helices and -strands are differently shaded. Structurally conserved 
residues are marked with asterisks, and amino acids residues of BTH and PH-20 protein 
corresponding to those within the active site of BVH are highlighted in bold type. 
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6.2.4 Potential binding mode of L-ascorbic acid-6-hexadecanoate at bo-
vine testicular hyaluronidase 
In order to identify the binding pocket of BTH the model was superimposed with the 
crystal structure of bee venom hyaluronidase in complex with a HA tetrasaccharide 
fragment. The active site of BTH was defined by the set of amino acids within a 
sphere of 4 Å around residues Tyr220 and Trp341 (BVH: Tyr184 and Trp301), both 
close to the reducing end of the tetrasaccharide and the amino acids Asp147 and 
Glu149 (BVH: Asp111 and Glu113) involved in catalysis. In the crystal structure of 
BVH, the aspartate and glutamate side chains are in close proximity − independent of 
whether an acidic or a neutral pH was used for crystallisation16 − and form a short 
hydrogen bond between both carboxylates. Therefore, Asp147 was treated un-
charged on docking simulations of compound 2.  
In analogy to the proposed hydrolysis mechanism of family 18 chitinases44,45 Glu113 
in BVH (equivalent to Glu149 in BTH) was proposed to act as the proton donor while 
the nucleophile is the acetamido oxygen of the HA substrate probably forming a co-
valent oxazolinium intermediate (see chapter 1, Figure 1.3). In the next step this 
intermediate is hydrolysed by a water molecule resulting in the observed retention of 
the configuration at the anomeric carbon atom.16,38,45 Like suggested for chitinase 
B,45 the protonation of Glu113 in BVH and Glu149 in BTH, respectively, should be 
simultaneous with substrate binding and the displacement of water molecules from 
the active site. However, it cannot be ruled out that on inhibitor binding Glu149 will 
not be protonated. Therefore, the δ-oxygen of Asp147 remains protonated in all flexi-
ble docking calculations whereas Glu149 is treated in both forms. 
Each of the FlexX calculations was analysed by visual inspection of the suggested 
docking poses (309 target-bound conformations for both residues uncharged, 237 for 
only Asp147 uncharged). Each docking series resulted in a preferred binding mode 
of compound 2 comprising about 70 % of all proposed poses. In both cases, the vi-
tamin C moiety acts as an anchor and is placed in such a way that an optimal hydro-
gen bonding pattern is achieved. In the case of both residues protonated (mode A), 
vitamin C interacts with the backbone oxygen atoms of Tyr263 and Tyr265 and with 
the side chain oxygen of Tyr279. In the other case (mode B), the hydrogen bonding 
interaction is formed with both amino acids relevant for catalysis, Asp147 and 
Glu149.  
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Figure 6.6. Comparison of proposed binding modes of compound 2 within the active site of the BTH 
models A: D147 and E149 uncharged, and B: only D147 uncharged. In panel A, the HA tetrasaccha-
ride fragment is additionally shown (carbon atoms coloured in yellow) as docked into the binding site 
of the BTH model according to the binding mode found in the crystal structure of bee venom hyalu-
ronidase (1fcv,16). The protein surface is represented by a Connolly surface coloured by lipophilicity 
(the warmer the colour, the more lipophilic the amino acids). Both catalytically active residues are 
shown with their protonation states used for the different calculations. 
Thus, the specific binding mode seems to depend on the protonation state of the 
catalytic residues as depicted in Figure 6.6A,B. If Asp147 and Glu149 are both un-
charged, the long alkyl chain of 2 occupies the region where the tetrasaccharide was 
found in the crystal structure of bee venom hyaluronidase (mode A, Figure 6.6A). In 
the other case the palmitoyl moiety projects to a channel-like region which probably 
belongs to the binding site of the polymeric HA before being degraded since it is di-
rectly attached to the site of the HA tetrasaccharide fragment (mode B, Figure 6.6B). 
Both of the proposed binding modes suggest a competitive binding mechanism of 2 
at BTH. Nevertheless, with respect to potential hydrophobic interactions, binding 
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mode A seems to be favoured. Depicting the hydrophobic surrounding of 2 by means 
of hydrophobicity-coloured Connolly surfaces shows that in this binding mode the 
long alkyl chain favourably interacts with an extended, strongly hydrophobic channel 
(brown colour) which is formed by mostly conserved amino acids Ala84, Leu91, 
Tyr93, Tyr220 and Leu344 in BTH (Phe46, Ile53, Tyr55, Tyr184 and Ser304 in BVH). 
In binding mode B the alkyl chain occupies a less hydrophobic region (green colour) 
(Figure 6.6A,B).  
For a further, more detailed experimental analysis of the mechanism of action of 2 
the hexasaccharide fragment of HA should be used. It is the proposed minimal sub-
strate46 enabling a degradation mechanism that can be evaluated by Michaelis-Men-
ten kinetics. These studies are currently under way.  
6.2.5 Comparison of binding modes of L-ascorbic acid and L-ascorbic 
acid-6-hexadecanoate at hyaluronidases  
The binding of L-ascorbic acid (1) at S. pneumoniae hyaluronate lyase is mainly 
caused by hydrophobic interactions with the side chain of Trp292, since the indole 
moiety is stacked with the five-membered ring of 1. This structural arrangement helps 
1 to bind in the narrowest part of the binding site comprising the amino acids Trp292, 
Arg462 and Arg466.26 In the L-ascorbic acid-6-hexadecanoate-S. pneunomiae 
hyaluronate lyase structure, the vitamin C moiety of the inhibitor is detected in the 
same narrow part of the active site, but it is mirrored (at a perpendicular plane 
through the centre of the ‘ring plane’). The alternative binding mode of 2 is probably 
forced by the long aliphatic side chain which forms strong hydrophobic interactions 
with residues of the hydrophobic patch. The ring-opened form in the crystal structure 
is no prerequisite of this mode since the intact vitamin C moiety may be docked in a 
similar position without changing interactions of the palmitoyl chain. 
Multiple binding modes for the vitamin C moiety are observed at the bacterial lyase 
which might also be principally possible at BTH. A first hint in this respect is given by 
the docking studies with L-ascorbic acid-6-hexadecanoate (2), since the L-ascorbic 
acid moiety is placed in two different, but adjacent parts of the active site of BTH 
(Figure 6.6A,B). This result probably follows from the topology of the HA binding site 
of BTH which is by far more open than that of the streptococcal enzymes. Interac-
tions of vitamin C itself may be too weak and/or immobilisation and orientation effects 
cannot sufficiently act on the small molecule within this wide crevice so that addi-
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tional hydrophobic substituents are needed to impart tight binding on BTH. In conclu-
sion, the observed selectivity of vitamin C for bacterial hyaluronidases vs. BTH 
seems to be due to a closer fit in a narrow binding pocket. 
6.3 Summary 
Hyaluronidases are enzymes degrading hyaluronan, an important component of the 
extracellular matrix. The mammalian hyaluronidases, e.g. the testicular PH20 protein 
and the lysosomal enzyme Hyal1, are considered to be involved in many 
(patho)physiological processes like fertilisation, tumour growth and metastasis. Bac-
terial hyaluronidases contribute to the spreading of microorganisms in the tissue. As 
the role of hyaluronidases is far from being clear, inhibitors are needed as pharma-
cological tools. Potent and selective inhibitors of hyaluronidases are not known up to 
now.  
Vitamin C (1) has been reported as a weak inhibitor of S. pneumoniae hyaluronidase. 
The X-ray structure of this enzyme in complex with vitamin C could be elucidated, 
suggesting that additional hydrophobic interactions might increase the inhibitory ac-
tivity. Consequently, we investigated L-ascorbic acid-6-hexadecanoate for its inhibi-
tory activity against streptococcal and bovine testicular hyaluronidase. With an IC50 
value of 4 µM, L-ascorbic acid-6-hexadecanoate (2) strongly inhibited S. agalactiae 
hyaluronidase, whereas. S. pneumoniae hyaluronidase and the bovine testicular 
hyaluronidase were inhibited with IC50 values of 100 µM and 56 µM, respectively. 
Compound 2 is thus up to 1500 times more active than vitamin C and is the most 
potent inhibitor of bacterial and bovine hyaluronidase described to date. 
To determine the binding mode, S. pneumoniae hyaluronidase was co-crystallised 
with 2. X-ray analysis confirmed the hypothesis that additional hydrophobic interac-
tions with Trp291, Phe343, His399, and Thr400 in the active site result in increased 
affinity. To predict the potential binding mode of 2 at bovine testicular hyaluronidase, 
a homology model of bovine testicular hyaluronidase based on the crystal structure 
of bee venom hyaluronidase was constructed by using MODELLER V6.2. Flexible 
docking with FlexX suggests two alternative binding modes of compound 2. With re-
spect to potential hydrophobic interactions, one binding mode seems to be clearly 
favoured. The long alkyl chain of L-ascorbic acid-6-hexadecanoate favourably inter-
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acts with an extended, strongly hydrophobic channel formed by mostly conserved 
amino acids Ala84, Leu91, Tyr93, Tyr220 and Leu344 in BTH. 
6.4 Materials and methods 
6.4.1 Materials 
Hyaluronic acid from S. zooepidemicus was purchased from Aqua Biochem (Dessau, 
Germany). Bovine serum albumin (BSA) was obtained from Serva (Heidelberg, Ger-
many). The investigated hyaluronidases were enzyme preparations from different 
sources.  
Lyophilised hyaluronidase from bovine testis (Neopermease), 200 000 IU (according 
to the declaration of the supplier; 4 mg) plus 25 mg gelatin per vial, was a gift from 
Sanabo (Vienna, Austria).  
Stabilised hyaluronate lyase, i.e., 200 000 IU (according to the declaration of the 
supplier) of lyophilised hyaluronidase (0.572 mg) from S. agalactiae , strain 4755, 
plus 2.2 mg BSA and 37 mg Tris–HCl per vial was kindly provided by id-Pharma 
(Jena, Germany). 
Streptococcus pneumoniae hyaluronate lyase5,9,47,48 has been produced as previ-
ously described.49 The enzyme was concentrated to 5 mg/ml in 10 mM Tris-HCl 
buffer, 150 mM NaCl, 1 mM DTT, (pH 7.4) using centrifugal spin devices with 50 kDa 
molecular weight cutoff (Millipore, Billerica, USA) and used for the inhibition studies 
and for crystallisation experiments. The enzyme concentration was determined pho-
tometrically at 280 nm using a calculated molar absorption coefficient49 of 127,090 
L·mol-1·cm-1 according to Pace et al.50 
L-ascorbic acid-6-palmitate was purchased from Sigma-Aldrich (Taufkirchen, Ger-
many). All other chemicals were of analytical grade and were obtained either from 
Merck (Darmstadt, Germany), from Fisher Scientific (Pittsburgh, USA) or Sigma 
Chemical (St. Louis, USA). Water was purified by a Milli-Q system (Millipore, 
Eschborn, Germany). Stock solutions of L-ascorbic acid and L-ascorbic acid-6-hexa-
decanoate in DMSO were prepared. 
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6.4.2 Activity and inhibition assays 
The inhibitory activities of vitamin C and L-ascorbic acid-6-hexadecanoate on the 
hyaluronidases from S. pneumoniae (hylSpn), from S. agalactiae, strain 4755 
(hylB4755), and from bovine testis (BTH) were measured using a turbidimetric assay 
according to the description of Di Ferrante.51 Enzyme activity was quantified by deter-
mining the turbidity caused by the remaining high molecular weight substrate (mo-
lecular weight > 6–8 kDa) precipitated with cetyltrimethylammonium bromide. The 
incubation mixture was composed of 120 µL of citrate-phosphate buffer (solution A: 
0.1 M Na2HPO4 / 0.1 M NaCl, solution B: 0.1 M citric acid / 0.1 M NaCl; solution A 
and B were mixed in appropriate portions to adjust pH 5.0), 30 µl of BSA solution (0.2 
mg BSA per mL of water), 30 µL of substrate solution (2 mg hyaluronic acid from S. 
zooepidemicus per mL of water), 50 µL H2O, 10 µL DMSO and 30 µL of enzyme so-
lution. To normalise the assays due to different enzymatic mechanisms of bacterial 
and bovine hyaluronidases equiactive concentrations of 54 ng of bovine testicular 
hyaluronidase, 2.9 ng of hyaluronidase from S. agalactiae, strain 4755 and 1.68 ng of 
hyaluronidase from S. pneumoniae in 30 µL of BSA solution were applied. To deter-
mine the enzyme activities in presence of the test compounds, instead of 10 µL 
DMSO, 10 µL of varying concentrations of both inhibitors were used resulting in a 
final concentration range of 1.1 µM to 300 µM for L-ascorbic acid-6-hexadecanoate 
and 1 mM to 100 mM for L-ascorbic acid and a final DMSO concentration of 3.8 % 
(v/v). 
After incubation of the assay mixture for 30 min at 37 °C, 720 µL of a 2.5 % (m/v) 
cetyltrimethylammonium bromide solution (2.5 g CTAB dissolved in 100 mL of 0.5 M 
sodium hydroxide solution, pH 12.5) were added to precipitate the residual high mo-
lecular weight substrate and to stop the enzyme reaction. This mixture was again 
incubated at 25 °C for 20 min and the turbidity of each sample was determined at 
600 nm with an Uvikon 930 UV spectrophotometer (Kontron, Eching, Germany). Ex-
periments were performed in quadruplicate. The turbidity of the sample without any 
inhibitor was taken as reference for 100 % enzyme activity (absorbance about 0.15), 
whereas the turbidity of the sample without enzyme (30 µL of BSA solution was used 
instead) was taken as reference for no degradation of HA (absorbance about 0.83). 
The activities were plotted against the logarithm of the inhibitor concentration, and 
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IC50 values were calculated by curve fitting of the experimental data with Sigma Plot 
8.0 (SPSS Inc., Chicago, USA). 
6.4.3 Crystallisation of the complex 
The crystallisation experiments were carried out by Masatoshi Nukui and Mark J. 
Jedrzejas (Children's Hospital Oakland Research Institute, Oakland, California 
94609, USA). For crystallisation experiments, L-ascorbic acid-6-hexadecanoate was 
dissolved in 5 % DMSO (v/v) and 10 mM Tris-HCl buffer, 150 mM NaCl, 1 mM DTT, 
pH=7.4 to the final concentration of 50 mM. The hanging drop vapour diffusion52 us-
ing Linbro culture plates53 at room temperature was used to grow the crystals of the 
enzyme-inhibitor complex. Equal volume of protein, reservoir solution (1µL each) and 
various amounts of inhibitor solutions (0.1, 0.5, and 1.0 µL) were mixed and equili-
brated against 1 mL of the reservoir solution. The reservoir solution contained satu-
rated ammonium sulfate, 0.2 M NaCl, 2 % dioxane, and 0.1 M sodium citrate buffer 
(pH 6.0) as reported for the native enzyme crystallisation.49 
6.4.4 X-ray diffraction 
The X-ray diffraction experiments were carried out by Masatoshi Nukui and Mark J. 
Jedrzejas (Children's Hospital Oakland Research Institute, Oakland, California 
94609, USA). The crystals of the enzyme-inhibitor complex were cryoprotected using 
30 % xylitol (w/v), 3.5 M ammonium sulfate and 0.1 M sodium citrate buffer (pH 6.0) 
as reported for the native crystals9 and frozen in liquid nitrogen. Standard fibre 
loops53 of a suitable size were used to pick up and mount the frozen crystals under a 
nitrogen flow at -180 °C. The X-ray diffraction data for the enzyme-inhibitor complex 
was collected using rotation (oscillation) photography and Quantum 4u CCD detec-
tor. The crystallographic setup of beamline 5.0.1 of the Berkeley Center for Structural 
Biology, Advanced Light Source, Lawrence Berkeley National Laboratory was used. 
The collected data were analysed, indexed, integrated, and scaled using the 
HKL2000 software package.54 The crystals were isomorphous to the native S. 
pneumoniae hyaluronate lyase crystals.49 The statistics of the native diffraction data 
were analysed. 
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6.4.5 Structure solution and refinement 
Structure solution and refinement were carried out by Daniel J. Rigden (National 
Centre of Genetic Resources and Biotechnology, Cenargen/Embrapa, Brasília, D.F. 
70770-900, Brazil). 
The structure was solved by rigid body refinement in CNS55 using the 1.56 Å crystal 
structure of S. pneumoniae hyaluronate lyase (PDB code 1egu;26) as a search 
model. Refinement employed alternating cycles of computational refinement with 
CNS55 and manual rebuilding using the programme O.56 All data were used through-
out with no intensity or sigma-based cut-offs applied. SigmaA-weighted map coeffi-
cients57 were used throughout. 
An Rfree value,55 calculated from 5 % of reflections set aside at the outset, was used 
to monitor the progress of refinement. Water molecules were placed into 3 positive 
peaks in |Fo-Fc| maps when density was also evident in |2Fo-Fc| maps and suitable 
hydrogen bonding partners were available. The ligand L-ascorbic acid-6-hexa-
decanoate was modelled into the catalytic site according to the strong, immediately 
evident difference density. Sulfate and xylitol molecules, deriving from the crystallisa-
tion and cryo-cooling solutions, respectively, were modelled into suitably shaped re-
gions of electron density. Final statistics for the model are shown in Table 6.2. 
Programs of the CCP4 package58 were applied to manipulations and structural 
superpositions made with LSQMAN.59 PYMOL60 was used for illustrations. 
 
Table 6.2. Crystallographic data and refinement statistics 
 
Space group 
 
P212121 
a (Å) 84.13 
b (Å) 102.71 
Unit cell 
c (Å) 102.4 
Low resolution diffraction limit (Å) 45.9 
High resolution diffraction limit (Å) 1.65 
Completeness1 99.9 (99.0) 
I/σ(I)1 22.8 (1.3) 
Multiplicity1 (%) 5.8 (5.7) 
L-ascorbic acid-6-hexadecanoate as potent hyaluronidase inhibitor
 
 105
Rmerge1 (%) 7.3 (87.5) 
Non-hydrogen protein atoms  5835 
Sulfate atoms 25 
Non-hydrogen atoms xylitol 30 
Non-hydrogen atoms compound 2 27 
Non-hydrogen atoms solvent 564 
Number of reflections1 106633 (9620) 
R (%)1 19.2 (30.5) 
Rfree (%)1 21.1 (31.4) 
All atoms 23.9 
Protein 22.2 
Protein main chain 21.2 
Protein side chain 22.5 
Sulfate 46.4 
Xylitol 38.1 
Compound 2  54.9 
vitamin C moiety 56.5 
palmitoyl moiety 46.8 
Mean temperature 
factor B (Å2) 
Solvent 31.1 
Bond lengths (Å) 0.005 rms deviation from 
ideal values Bond angles (º) 1.2 
1
 Values in brackets are for the highest resolution shell, 1.65 - 1.60 Å. 
 
 
6.4.6 Construction of bovine testicular hyaluronidase model 
All calculations were done on a SGI OCTANE R10000 workstation. For homology 
modelling of bovine testicular hyaluronidase (BTH) the crystal structures of bee 
venom hyaluronidase16 were used as templates (pdb codes: 1fcq, 1fcu and 1fcv). 
Since the sequence identity between BTH and bee venom hyaluronidase is only 
32 %, a multiple sequence alignment including the human PH-20 protein was per-
formed to get more reliable results. The amino acid sequence of BTH61 was aligned 
with the sequences of bee venom hyaluronidase extracted from the crystal structures 
and of the human PH-20 protein (Swiss-Prot Accession Number: p38567) using the 
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program ClustalW.36 After manual refinement of the sequence alignment a homology 
model was generated with the help of MODELLER version 6.2.39-41 The resulting 
model was evaluated for correct local geometry using Procheck42,43 and the SYBYL 
module ProTABLE. Then the model was protonated using SYBYL 6.8 (Tripos Inc., 
St. Louis) and energetically minimised with the AMBER all-atom force field62 with AM-
BER all-atom charges (distance dependent dielectricity constant 4) up to a root mean 
square (rms) gradient of 0.1 kcal/mole•Å (Powell conjugate gradient). Surfaces and 
lipophilic potentials of the model were calculated and visualised by the program 
MOLCAD implied in SYBYL 6.8. 
6.4.7 Flexible docking of L-ascorbic acid-6-hexadecanoate using FlexX  
The 3D structure of 2 was generated with the SYBYL SKETCH module and energeti-
cally minimised using the Tripos Force Field with Gasteiger-Hückel charges (distance 
dependent dielectricity constant 1) up to a root mean square (rms) gradient of 0.05 
kcal/mole•Å (Powell conjugate gradient). The binding pocket of BTH was defined by 
the amino acids within a sphere of 4 Å around Tyr220 and Trp341. All docking cal-
culations were performed with FlexX version 1.12.63-65 Previous versions of FlexX 
tended to overestimate affinity of hydrogen bonded ligands and performed poor with 
relatively lipophilic binding sites.66 Due to the amphiphilic substrate hyaluronan the 
active site of BTH consists of many polar, mostly ionic amino acids, but contains also 
some hydrophobic residues (see Figure 6.5). Therefore we used the recently devel-
oped scoring function ScreenScore which incorporates hydrophobic67 and hydrogen 
bond score contributions with more realistic weights. It was introduced for use in 
FlexX by Stahl et al. in a detailed analysis of scoring functions for virtual screening.66 
Apart from water particle placement64 and ScreenScore as fitness and scoring func-
tion, standard parameters were applied. The results were analysed and visualised 
with FlexV version 1.6 and SYBYL 6.8. 
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Chapter 7 3D pharmacophore derivation for struc-
ture-based ligand design of hyaluronate lyase inhibi-
tors 
7.1 Introduction 
The interaction of biologically active ligands with biopolymers, mostly proteins (re-
ceptors, enzymes, ion channels), at the molecular level is the fundamental key for 
rational drug design which at best needs structural information about both of the in-
teracting molecules. Therefore, the preferred starting points for rational drug design 
are three-dimensional (3D) structures of protein targets.1,2 
If a 3D structure is available, three distinct design strategies may be pursued de-
pending on additional information about the target of interest. The most laborious 
case applies if the binding site is unknown. Then pockets or cavities predominating 
as binding sites may be detected by computational tools like LIGSITE,3 PASS,4 
SiteID5 etc. In the second case, the approximate binding region is known, but no spe-
cific interactions between ligands and individual amino acids have been identified. 
This requires a careful search for sites most favourable for interaction. Suitable pro-
grammes in that respect are LUDI,6,7 SUPERSTAR,8 and GRID9 etc. which identify 
´hot spots´ of binding. This knowledge can be transferred into pharmacophore mod-
els for database searching. The most straightforward case applies if the binding site 
and crystal structures complexed with ligands are known. Based on the exploration of 
individual interactions and spatial conditions, docking and virtual screening ap-
proaches are possible.1 Recently, the latter approaches were successfully combined 
in de novo ligand design projects using protein-derived 3D pharmacophores in virtual 
screening.10-12 
In this chapter, the binding modes of two inhibitors (see Figure 7.1) co-crystallised 
with S. pneumoniae hyaluronate lyase (hylSpn) are compared (see also chapter 6 
and reference 13). In consideration of this analysis and with the help of the pro-
grammes LUDI and GRID, hylSpn regions where H-bond donor, H-bond acceptor 
and hydrophobic moieties of inhibitors most favourably bind are identified and trans-
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ferred into a 3D pharmacophore model. This model might serve as basis for a virtual 
screening approach with UNITY or CATALYST. 
7.2 Results and discussion 
7.2.1 Comparison of binding modes of a 2-phenylindole based inhibitor 
and L-ascorbic acid-6-hexadecanoate at S. pneumoniae hyaluroni-
dase 
The detection of indole-2-carboxylic acid as hit in LUDI searches for bacterial hyalu-
ronate lyase inhibitors (see chapter 3) has inspired us to investigate further 2-substi-
tuted indole derivatives.13 By means of X-ray crystallography, the binding mode of 
one of these compounds, sulfamic acid 1-decyl-2-(4-sulfamoyloxy-phenyl)-1H-indol-
6-yl ester (1) at hylSpn was elucidated (see Figure 7.2).13,14 Hydrophobic interactions 
of the rings and the aliphatic chain as well as hydrogen bonds with the sulfonamide 
group in position 6 of the indole moiety are obvious. The indole ring is bound on one 
side by Trp292, with both ring planes stacking at proper distance. The other side of 
the indole ring is in contact with the guanidinium group of Arg462. Such cation-pi in-
teractions can be highly favourable.15 The phenyl moiety forms an approximately per-
pendicular ring arrangement with Trp291. The aliphatic tail fits in a surface crevice 
shaped mainly by the hydrophobic residues Met579, Trp291 and Phe343. The sulfa-
moyloxy group (attached to the phenyl moiety) for which electron density was com-
pletely lacking is presumably oriented outwards and solvent-exposed. 
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Figure 7.1. Chemical structures of the hyaluronate lyase inhibitors sulfamic acid 1-decyl-2-(4-
sulfamoyloxy-phenyl)-1H-indol-6-yl ester (1) and L-ascorbic acid-6-hexadecanoate (2). 
As shown in chapter 6, the binding mode of L-ascorbic acid-6-hexadecanoate (2), the 
representative member of a series of novel hyaluronate lyase inhibitors, at hylSpn 
was determined by X-ray crystallography, too. As depicted in Figure 7.2 for compari-
son with compound 1, the binding of the different inhibitors causes no significant 
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conformational changes in the protein structure. The unexpectedly ring-opened vita-
min C moiety of 2 (see chapter 6) binds in exactly the same position of the catalytic 
site as the indole ring of 1. Also the aliphatic tails of both compounds (in the case of 2 
with 16 carbons of which 13 were detected) binds in the same surface crevice with 
similar orientation. Only the conformations of the aliphatic chains are slightly different 
due to the presence of the phenyl ring in compound 1. In particular, the tail of 1 binds 
closer to Tyr408 and His399. A further difference is evident at the distal end of the 
chains. The shorter length of the tail of 1 enables the distal end to dock into a surface 
pocket, whereas the terminus of the palmitoyl group of L-ascorbic acid-6-hexa-
decanoate is solvent-exposed.  
 
Figure 7.2. Comparison of binding modes of the S. pneumoniae hyaluronate lyase inhibitors sulfamic 
acid 1-decyl-2-(4-sulfamoyloxy-phenyl)-1H-indol-6-yl ester (1, carbon atoms coloured in orange) and 
L-ascorbic acid-6-hexadecanoate (2, carbon atoms coloured in grey). 
7.2.2 Development of a 3D pharmacophore derived from inhibitor bind-
ing sites 
An important basis of structure-based ligand design is the exact knowledge of the 
ligand binding sites mostly deduced by crystallographic complexes. Recently, a strat-
egy of virtual database screening using 3D pharmacophores derived from the crystal 
structures proved to be very efficient with respect to lead finding. In this procedure, 
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the essential binding features of complexed ligands are considered and favourable 
interaction sites are calculated, resulting in a complex pharmacophore used for vir-
tual screening.10,11  
The programmes LUDI6,7 and GRID version 219 were applied to highlight those areas 
of the binding site where putative ligands can interact with the protein. LUDI places 
potential interaction sites for hydrogen bond donors, acceptors and hydrophobic 
groups within the binding pocket according to a set of rules which have been derived 
from composite crystal-field environments observed in the crystal packing of small 
organic molecules.16 GRID is based on a force-field approach. The interaction poten-
tial is calculated for a variety of different probes at the intersections of a regularly 
spaced grid embedded in the binding pocket.  
The binding pocket was systematically searched with three probes: a lipophilic probe 
and two probes representing H-bond acceptors and donors, respectively. LUDI and 
GRID highlighted qualitatively similar regions called ’hot spots’ but the maps differed 
quantitatively due to different relative weightings. As shown in Figure 7.3A, place-
ment of an NH group in a ligand is favourable between the amino acid residues 
Asn349 and His399 as well as below Trp292 (centre of figure). A rather large ‘hot 
spot’ is situated below Asn349, approximately at the distal end of the decyl tail of 
compound 1 (see Figure 7.2), resulting from the amino acid residues Glu388 and 
Asp398 (not shown in Figure 7.3A). This region is only accessible for ligands with 
rather large substituents like compound 1 (see above). All other ‘hot spots’ lie beyond 
the ‘inner’ active site of hylSpn, thus probably inaccessible by small lead structures.  
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Figure 7.3. Putative binding ’hot spots’ in hylSpn. A) Possible positioning of hydrogen donor groups in 
ligands. LUDI interaction sites generated for a NH group are shown as vectors. GRID contour surfaces 
are coloured in magenta. B) Possible positioning of hydrogen acceptor groups in ligands. LUDI inter-
action sites generated for a C=O group are shown as vectors. GRID contour surfaces are coloured in 
yellow. 
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Figure 7.4. Putative hydrophobic ‘hot spots’ in hylSpn. Possible positioning of lipophilic groups in 
ligands. LUDI interaction sites generated for a lipophilic carbon atom are shown as dots. GRID contour 
surfaces are coloured in red. 
The H-bond acceptor ‘hot spots’ induced by Arg462 and Arg466 as well as Arg462, 
Tyr408 and Asn349 (centre of the figure) are rather distinct. An additional ‘hot spot’ 
results from the NH group of Trp291.  
The hydrophobic regions can be visualised more easily by the GRID maps (see 
Figure 7.4) because of the wide scattering of the hydrophobic centres calculated by 
LUDI. However, increased density of these centres is observed along the side chains 
and parallel to the ring planes of Trp292 and His399, coinciding with the GRID maps. 
The lower hydrophobic region is also induced by Met579 (not shown in Figure 7.4).  
The ‘hot spots’ for each of the three probes could be converted into a 3D pharma-
cophore model that might be queried by the database mining programmes UNITY5 or 
CATALYST.17 A schematic representation of this pharmacophore in relation to the 
position of compound 1 in the crystal structure is depicted in Figure 7.5. One H-bond 
donor region is located above the carbonyl group of the side chain of Asn349 (see 
Figure 7.3A). Four regions for favourable placement of H-bond acceptors in the mole-
cules due to Asn349, Tyr408 and Arg462/Arg466 are placed in the centre of the 
search sphere (see Figure 7.3B). Additionally, the two large hydrophobic regions 
(see Figure 7.4) described above are included in the pharmacophore. 
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Figure 7.5. Schematic representation of the 3D pharmacophore model derived from the 'hot spots'. 
Hydrophobic regions (red), hydrogen donor (magenta) and hydrogen acceptor sites (yellow) are de-
picted as ellipses and arranged in relation to the position of compound 1 in the crystal structure. 
7.2.3 Hyaluronate lyase inhibitor design based on known binding modes 
For reasons of economy we have not purchased database mining programmes for 
queries with the 3D pharmacophore described above up to now. However, this model 
as well as the binding modes of compounds 1 and 2 compared in Figure 7.2 may 
serve for the design of novel hyaluronate lyase inhibitors on the basis of the following 
rational considerations, too. 
The first question is whether the structure-activity relationships (SAR) of 2-phenylin-
dole derivatives, e.g. compound 1 and compounds 6a-f (see Table 7.1 and reference 
13) correlate with the pharmacophore model. (Of course, this implies that the binding 
modes of the inhibitors at hylSpn and hylB4755 are similar. This may be anticipated 
because of the very high sequence identity of the active sites.) Comparing the activi-
ties of compounds 6a and 6b, the methyl group in position 3 does not lead to signifi-
cant loss of inhibitory activity. Thus, due to increased compound stability, the 3-Me 
substituent was retained in compounds 6c-f.13  
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By simple inspection of Figure 7.2, a binding mode of compounds 6b-f analogous to 
that of compound 1 with directly overlaying indole moieties seems to be less prob-
able. Presumably, the additional methyl group would lead to bumps with the amino 
acid residue Asn290. The distance between the nitrogen atom of the asparagine 
residue and the carbon atom C-3 of the indole ring is only 2.9 Å, so that the required 
space for a methyl group would be too small. Possibly the side chain of Asn290 is 
rotated, thereby eliminating any sterical hindrance. Furthermore, the coplanar orien-
tation of the phenyl and the indole ring as observed for compound 1 in the crystal 
structure could be more or less distorted. Interestingly, the introduction of a 5-hy-
droxy substituent in compounds 6a-f does not generally reduce the inhibitory activity 
compared to the 6-sulfamoyloxy group in 1. It may therefore be concluded that the 5-
OH oxygen atom occupies one of the H-bond acceptor regions depicted in Figures 
7.3B and 7.5. The increasing hylB4755 inhibition with increasing chain length of the 
alkyl substituents at the nitrogen atom of the indole moiety clearly indicates that the 
binding mode of compounds 6c-f is similar to that found for compound 1. Probably, 
the aliphatic chains occupy the same crevice as the decyl substituent of compound 1. 
The ‘hot spot’ analysis for the hydrophobic map supports the SAR because favour-
able hydrophobic interactions (see Figure 7.4) were proposed where the aliphatic 
tails of compounds 1 and 2 are found in the X-ray structures (see Figure 7.2). In 
conclusion, the SAR of compounds 6a-f are largely compatible with the 3D pharma-
cophore model derived above. 
Based on the identification of 1,3-diacetylbenzimidazole-2-thione (3, Figure 7.6) as 
hyaluronate lyase inhibitor (see chapter 3), benzoxazole-2-thione derivatives (4) were 
found to inhibit hylB4755.18 All inhibitors of the benzoxazole type (4) found to date 
incorporate an alkoxy chain as substituent at the nitrogen atom (R = CH3 and 
C5H11).18 The SAR of the 2-phenylindole derivatives are reproduced since hylB4755 
inhibition is increased with increasing chain length of R. It may therefore be con-
cluded that both benzoxazole-2-thione derivatives have a binding mode similar to 
that of compound 1, i.e., the benzoxazole moiety overlays with the indole moiety and 
the alkoxy substituents of 4 point into the same direction like the aliphatic tail of com-
pound 1. In this case, the amide oxygen might even occupy one of the hydrogen ac-
ceptor sites (see Figures 7.2, 7.3B and 7.5).  
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Figure 7.6. Chemical structures of hylB4755 inhibitors 1,3-diacetylbenzimidazole-2-thione (3), benzoxa-
zole-2-thiones 4 and the proposed derivatives 5. 
 
Figure 7.7. Comparison of binding modes of hylSpn inhibitor sulfamic acid 1-decyl-2-(4-sulfamoyloxy-
phenyl)-1H-indol-6-yl ester (1, carbon atoms orange) and a substrate-based hexasaccharide (carbon 
atoms purple, for sake of clarity only a trisaccharide moiety is shown). 
Starting from these considerations, a comparison of the binding modes of compound 
1 and a substrate-based hexasaccharide was envisaged to rationally derive novel 
benzoxazole derivatives with the help of observed crystallographic hylSpn data. As 
shown in Figure 7.7, the depicted trisaccharide overlaps with compound 1. Focussing 
on substituents at the nitrogen atom of the benzoxazole moiety, 3-substituted propi-
onic acid derivatives are promising since a N-acetylglucosamine residue of the HA 
substrate is observed in the region where the methylene groups 4 and 5 of the decyl 
substituent of compound 1 are found (Figure 7.7).  
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Table 7.1. IC50 values of the synthesised 2-phenylindole derivatives (1, 6a-f) determined on the 
hyaluronate lyase hylB4755 (n=3; SEM not larger than 1 %)13 
N
R4R2
R1
R3
 
1, 6a-f 
No. 
 
Substitution 
hylB4755 
IC50/µM or  
(% inhibition)a 
  R1 R2 R3 R4 pH 5.0 pH 7.4 
 
 
    
  
1  H 6-OSO2NH2 C10H21 OSO2NH2 11 16 
6a  H 5-OH H OH (75 %)b 160 
6b  CH3 5-OH H OH 740 280 
6c  CH3 5-OH CH3 OH 480 220 
6d  CH3 5-OH C3H7 OH 220 160 
6e  CH3 5-OH C5H11 OH 23 36 
6f  CH3 5-OH C7H15 OH 26 12 
a
 at concentrations ≤ 100 µM unless otherwise indicated 
b
 1000 µM 
 
Based on this assumption, all proposals should share a common motif (derivatives 5, 
Figure 7.6): a benzoxazole moiety as anchor in the upper part of the binding site, a 
propionic acid as spacer, and a variety of ring-based substituents as R’ like mor-
pholine, piperazine, cyclohexyl, phenyl, 4-carboxyphenyl etc. occupying the space of 
the N-acetylglucosamine residue. The synthesis of representative compounds is 
subject of ongoing work. Very recently, the phenyl derivative of 5 (R’ = Ph) was found 
to be a potent inhibitor of hylB4755 with an IC50 value of 15 µM at pH 5.0 (optimum 
pH).18 This promising result strengthens the proposed structure-based design strat-
egy. 
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7.3 Summary 
Starting from elucidation of two hyaluronate lyase-inhibitor complexes, the binding 
modes of sulfamic acid 1-decyl-2-(4-sulfamoyloxy-phenyl)-1H-indol-6-yl ester (1) and 
L-ascorbic acid-6-hexadecanoate (2) were analysed revealing that the unexpectedly 
ring-opened vitamin C portion of 2 binds in exactly the same part of the catalytic site 
as the indole ring of 1. Additionally, the long aliphatic substituents of both compounds 
bind in the same surface crevice. With the help of the programmes LUDI and GRID, 
regions where H-bond donor, H-bond acceptor and hydrophobic moieties of inhibitors 
may bind most favourably were identified and transferred into a 3D pharmacophore 
model. This model might serve as basis for a virtual screening approach with UNITY 
or CATALYST. 
The analysis of known SAR of 2-phenylindole derivatives with respect to the ob-
served binding mode of compound 1 at hylSpn and to the 3D pharmacophore model 
led to suggestions for the binding mode of benzoxazole-2-thione derivatives (4). 
Based on the superposition of the crystal structure of hylSpn in complex with com-
pound 1 and a substrate-based hexasaccharide, novel benzoxazole-2-thiones (5) 
with 3-substituted propionic acid groups at the nitrogen atom were predicted as puta-
tive hyaluronate lyase inhibitors. Very recently, this design strategy was confirmed by 
the phenyl derivative of 5 which is a potent inhibitor of hylB4755 with an IC50 value of 
15 µM. 
7.4 Theoretical methods 
7.4.1 Analysis and comparison of the crystal structures of S. pneumo-
niae hyaluronate lyase in complex with a 2-phenylindole based in-
hibitor and L-ascorbic acid-6-hexadeacanoate 
The crystal structures of S. pneumoniae hyaluronate lyase in complex with sulfamic 
acid 1-decyl-2-(4-sulfamoyloxy-phenyl)-1H-indol-6-yl ester13 and L-ascorbic acid-6-
hexadeacanoate (chapter 6) were elucidated in cooperation with M. J. Jedrzejas 
(Children's Hospital Oakland Research Institute, Oakland, California) and D. Rigden 
(National Centre of Genetic Resources and Biotechnology, Cenargen/Embrapa, 
Brasília, Brazil). After superposition of both crystal structures common features of 
both binding modes were extracted for further structure-based inhibitor design. 
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7.4.2 Protein-derived pharmacophore  
A pharmacophore has been developed by directly extracting favourable interaction 
sites from the region of the hylSpn crystal structure where the inhibitors bind. To 
highlight those areas of the binding site where a putative ligand can favourably inter-
act with the protein, we applied LUDI6,7 and GRID9 as alternative methods. The ac-
tive site of hylSpn derived from the binding pockets of the aforementioned co-crystal-
lised ligands (see reference 13 and chapter 6) was systematically searched for favour-
able interactions with the following functional groups: C=O (H-bond acceptor), an 
amide NH group (H-bond donor), and a lipophilic group to describe hydrophobic in-
teractions. The centre of the LUDI search sphere with a radius of 10 Å is defined so 
that both co-crystallised ligands are centred and fully enclosed in the sphere. In the 
case of GRID, the O and N1 probes as well as the lipophilic DRY probe were se-
lected for the analysis. The side length of the grid box is set to 10 Å, and its centre 
coincides with that defined for the LUDI calculation. In addition, all lipophilic moieties 
observed in crystal structures of protein-ligand complexes with hylSpn were superim-
posed in order to merge the information from the different contouring methods with 
those of the known binding modes.  
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Chapter 8 Summary 
Hyaluronan and hyaluronidases have been used in several medical fields for many 
years. For example, sodium hyaluronate is frequently applied in the treatment of os-
teoarthritis, whereas preparations of bovine testicular hyaluronidase are useful in the 
therapy of different diseases in internal medicine, ophthalmology and orthopaedia. It 
has been reported that some hyaluronidases play a role in, e.g., meningitis, septi-
caemia, arthroses and cancer. To further investigate the function of hyaluronic acid 
and hyaluronidases in physiological and pathophysiological processes, selective and 
potent hyaluronidase inhibitors are required. Originated by the lack of such com-
pounds, the main goal of this thesis was the prediction and selection of lead-like 
structures by de novo ligand design and virtual screening of generated compound 
libraries. 
For structure-based ligand design with the de novo design programme LUDI, a ho-
mology model of S. agalactiae strain 4755 hyaluronate lyase was constructed start-
ing from two crystal structures of the related enzymes from S. pneumoniae and 
S. agalactiae strain 3502. Screening of the three databases LeadQuest® Vol. 1&2, 
Accelrys and the adapted ChemACX database (ChemACXF) resulted in 1275 hits. 
Of the 19 compounds selected for synthesis and testing, 13 were active on 
S. agalactiae strain 4755 hyaluronan lyase in the milli- and submillimolar range.‡‡‡ 
1,3-Diacetylbenzimidazole-2-thione was identified to be one of the most potent in-
hibitors of hyaluronate lyases described to date (IC50 values of 5 µM and 160 µM at 
physiological pH and optimum pH, respectively). Based on the results of all investi-
gated compounds, an additional approach combining virtual screening by pharma-
cophore filters with validation of scoring functions was applied. Using the re-scoring 
scheme with X-Score and subsequently the automated flexible docking programme 
FlexX, a double-docking-double-scoring strategy was derived which seems to im-
prove the selection and lead optimisation of hyaluronate lyase inhibitors. 
                                            
‡‡‡
 Purchase, synthesis and pharmacological investigations of the selected compounds were subject 
of the PhD thesis of Sunnhild Salmen, Universität Regensburg, 2003. 
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To validate the usage of the LeadQuest® (Vol. 1&2 and Vol. 1-3), the Accelrys and 
the ChemACXF databases in further virtual screening approaches, the distribution of 
six (physico)chemical properties (molecular weight, log P, numbers of H-bond donor 
and acceptor atoms, numbers of rotatable bonds and of rings) within these data-
bases were analysed with respect to drug-likeness. The analysis revealed that the 
further development of the LeadQuest® database from Vol. 1&2 to Vol. 1-3 led to a 
compound selection which contains more drug-like molecules than its ancestor with 
respect to all examined properties except for molecular weight. Furthermore, the 
rather raw pre-filtering of the ChemACX database as compound selection of com-
mercially available molecules by elimination of reactive compounds and of entities 
outside a certain molecular weight range resulted in a database with property distri-
butions significantly different from those of the LeadQuest® databases, though cov-
ering the essential pharmacological space. Thus, the LeadQuest® databases Vol. 1-3 
as well as the reduced ChemACX database are likewise suited for the selection of 
potential drugs and provide a robust basis for virtual screening with the programme 
LUDI. 
A property analysis for the potential hyaluronate lyase inhibitors, i.e., the de novo 
design hits from the LeadQuest® and ChemACXF databases, in comparison to the 
property distributions in the original databases should give insights into the capability 
of the programme LUDI to extract molecules meeting the LUDI-derived pharma-
cophore features with similar (physico)chemical properties. Obviously the screening 
filter of LUDI (the pharmacophoric properties of the hyaluronate lyase binding site) 
generates a constrained but allowed pharmacological space represented by typical 
ranges of molecular weights, log P values, numbers of H-bond donor and acceptor 
atoms, and numbers of rotatable bonds. Thus, these ranges are subranges with re-
spect to the property distributions of the databases used which cover most of the 
‘potential pharmacological space’. 
For de novo design of inhibitors of bovine testicular hyaluronidase (BTH) with the 
programme LUDI, a homology model of the enzyme based on crystal structures of 
bee venom hyaluronidase was constructed with the help of MODELLER. Filtering of 
the LeadQuest® databases Vol. 1-3 and the ChemACXF database resulted in more 
than 5500 hits. Five compounds were selected for testing hyaluronidase inhibition. 
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Unfortunately, none of the compounds inhibited BTH, probably due to their poor 
solubility. To possibly overcome this failure by less lipophilic compounds, an addi-
tional, ligand-based approach was performed. The superposition of the active sites of 
the BTH model, the crystal structures of bee venom hyaluronidase and the bacterial 
chitinases A and B in complex with inhibitors revealed a very good overlap of the 
amino acids involved in catalysis and of the co-crystallised ligands (HA tetrasaccha-
ride fragment, allosamidin and CI-4). By considering essential substructures mim-
icking the proposed intermediate of hyaluronic acid hydrolysis and by introducing 
suitable substituents suggested to interact with amino acids of the active site of the 
bovine enzyme, two compounds were proposed as potential inhibitors of BTH. 
Based on the finding that vitamin C weakly inhibits S. pneumoniae hyaluronidase, the 
more hydrophobic vitamin C derivative L-ascorbic acid-6-hexadecanoate was inves-
tigated and proved to be a potent inhibitor of S. agalactiae hyaluronidase, S. pneu-
moniae hyaluronidase and BTH with IC50 values of 4 µM, 100 µM and 56 µM, re-
spectively. L-ascorbic acid-6-hexadecanoate is the most potent inhibitor of bacterial 
and bovine hyaluronidase described to date. 
The binding mode of L-ascorbic acid-6-hexadecanoate at S. pneumoniae hyaluroni-
dase was determined by X-ray analysis§§§, supporting the hypothesis that additional 
hydrophobic interactions with Trp291, Phe343, His399, and Thr400 in the active site 
contribute to the high affinity. To predict the potential binding mode of L-ascorbic 
acid-6-hexadecanoate at BTH, flexible docking of the compound with FlexX was 
performed suggesting two alternative binding modes. With respect to potential hy-
drophobic interactions, that binding mode seems to be clearly favoured where the 
long alkyl chain of L-ascorbic acid-6-hexadecanoate favourably interacts with an ex-
tended, strongly hydrophobic channel formed by the mostly conserved amino acids 
Ala84, Leu91, Tyr93, Tyr220 and Leu344. 
Starting from elucidation of two hyaluronate lyase-inhibitor complexes, the binding 
modes of sulfamic acid 1-decyl-2-(4-sulfamoyloxy-phenyl)-1H-indol-6-yl ester and L-
ascorbic acid-6-hexadecanoate were analysed indicating that the vitamin C portion of 
                                            
§§§
 These studies were performed in cooperation with M. J. Jedrzejas (Children's Hospital Oakland 
Research Institute, Oakland, California 94609, USA). The X-ray structure of the complex was solved 
by D. Rigden (National Center of Genetic Resources and Biotechnology, Cenargen/Embrapa, Brasília, 
D.F. 70770-900, Brazil). 
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L-ascorbic acid-6-hexadecanoate binds in exactly the same region of the catalytic 
site as the indole ring of sulfamic acid 1-decyl-2-(4-sulfamoyloxy-phenyl)-1H-indol-6-
yl ester. Additionally, the long aliphatic substituents of both compounds bind in the 
same surface crevice. With the help of the programmes LUDI and GRID, regions 
where H-bond donor, H-bond acceptor and hydrophobic moieties of inhibitors may 
interact most favourably were identified and transferred into a 3D pharmacophore 
model. This model might serve as basis for a virtual screening approach with UNITY 
or CATALYST. 
The analysis of known SAR of 2-phenylindole derivatives with respect to the ob-
served binding mode of sulfamic acid 1-decyl-2-(4-sulfamoyloxy-phenyl)-1H-indol-6-
yl ester at S. pneumoniae hyaluronate lyase and to the 3D pharmacophore model led 
to suggestions about the binding mode of benzoxazole-2-thione derivatives. Based 
on the superposition of the crystal structure of this bacterial lyase in complex with the 
co-crystallised indole derivative and a substrate-based hexasaccharide, novel ben-
zoxazole-2-thiones with 3-substituted N-propanoyl groups were predicted as putative 
hyaluronate lyase inhibitors. This design strategy was confirmed by the activity of the 
3-phenylpropanoyl derivative which potently inhibits S. agalactiae strain 4755 hyalu-
ronate lyase
 
with an IC50 value of 15 µM. 
In summary, ligand-based and structure-based approaches led to the identification of 
hyaluronidase inhibitors with (sub)micromolar activity. Especially by de novo design, 
potent hyaluronate lyase inhibitors were obtained. Further work is necessary to de-
sign inhibitors of mammalian hyaluronidases which can be used as pharmacological 
tools to study the role of the enzyme and its substrate, hyaluronic acid, in physiologi-
cal and pathophysiological processes. 
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Chapter 9 Appendix 
List of abbreviations 
2D  two-dimensional 
3D  three-dimensional  
ACD  Available Chemical Directory 
ADMET  absorption, distribution, metabolism, excretion, toxicity 
BSA  bovine serum albumin 
BTH  bovine testicular hyaluronidase 
BVH  bee venom hyaluronidase 
CADD  Computer-aided drug design 
CTAB cetyltrimethylammonium bromide 
ChiA  chitinase A 
ChiB  chitinase B 
CI-4  cyclo-(L-Arg-D-Pro) 
CMC  Comprehensive Medicinal Chemistry 
DMSO  dimethylsulfoxide 
DTT  dithiothreitol 
HA  hyaluronic acid  
HTS  high-throughput screening 
hylSpn  S. pneumoniae hyaluronidase 
hylB3502  S. agalactiae strain 3502 hyaluronate lyase 
hylB4755  S. agalactiae strain 4755 hyaluronate lyase 
IC50  concentration of an inhibitor required to give 50 %  
 inhibition of enzyme activity 
IU international units 
Kd equilibrium dissociation constant 
Ki inhibition constant 
Km Michaelis constant; concentration of a substrate at which 
 reaction rate is half maximal 
lg  log 
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log P  logarithm of the partition coefficient 
M  mol/L 
min  minute 
MW  molecular weight 
NCE  database of New Chemical Entities 
PMF  potential of mean force 
QSAR  quantitative structure-activity relationships 
rms  root mean square 
SAR  structure-activity relationships 
SCR  structurally conserved regions 
UV  ultra violet 
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